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ABSTRACT OF THE DISSERTATION 
Sequence analysis methods for the design of cancer vaccines that target tumor-specific 
mutant antigens (neoantigens) 
by 
Jasreet Hundal 
Doctor of Philosophy in Biology and Biomedical Sciences 
Human & Statistical Genetics 
Washington University in St. Louis, 2018 
Professor Elaine R Mardis, Chair 
Professor Malachi Griffith, Co-Chair 
 
 
The human adaptive immune system is programmed to distinguish between self and non-self 
proteins and if trained to recognize markers unique to a cancer, it may be possible to 
stimulate the selective destruction of cancer cells. Therapeutic cancer vaccines aim to boost 
the immune system by selectively increasing the population of T cells specifically targeted to 
the tumor-unique antigens, thereby initiating cancer cell death.. In the past, this approach  has 
primarily focused on targeted  selection of ‘shared’ tumor antigens, found across many 
patients. The advent of massively parallel  sequencing and specialized analytical approaches 
has enabled more efficient characterization of tumor-specific mutant antigens, or neoantigens. 
Specifically, methods to predict which tumor-specific mutant peptides (neoantigens) can 
elicit anti-tumor T cell recognition  improve predictions of immune checkpoint therapy 
response and identify one or more neoantigens as targets for personalized vaccines. Selecting 
the best/most immunogenic neoantigens from a large number of mutations is an important 
challenge, in particular in cancers with a high mutational load, such as melanomas and 
 
 
 xii 
smoker-associated lung cancers. To address such a challenging task, Chapter 1 of this thesis 
describes a genome-guided in silico approach to identifying tumor neoantigens that integrates 
tumor mutation and expression data (DNA- and RNA-Seq). The cancer vaccine design 
process, from read alignment to variant calling and neoantigen prediction, typically assumes 
that the genotype of the Human Reference Genome sequence surrounding each somatic 
variant is representative of the patient’s genome sequence, and does not account for the effect 
of nearby variants (somatic or germline) in the neoantigenic peptide sequence. Because the 
accuracy of neoantigen identification has important implications for many clinical trials and 
studies of basic cancer immunology, Chapter 2 describes and supports the need for patient-
specific inclusion of proximal variants to address this previously oversimplified assumption 
in the identification of neoantigens. The method of neoantigen identification described in 
Chapter 1 was subsequently extended (Chapter 3) and improved by the addition of a modular 
workflow that aids in each component of the neoantigen prediction process from neoantigen 
identification, prioritization, data visualization, and DNA vaccine design.  These chapters 
describe massively parallel sequence analysis methods that will help in the identification and 
subsequent refinement of patient-specific antigens for use in personalized immunotherapy.
 
 
 1 
Chapter 1: Introduction & Background 
 
1.1 Introduction 
After the landmark discovery of the double helix structure of deoxyribonucleic acid (DNA) in 
1953 by Watson and Crick, coupled with several advances in molecular biology techniques, 
specifically the dideoxynucleotide sequencing techniques of  Sanger, the completion of the 
human reference sequence in 2004, and the development of basic computational DNA 
analysis and annotation software, heralded a new era for disease research1. ‘Finishing’ the 
first human reference genome sequence provided a new roadmap to understanding where 
genes in the genome were located and organized on chromosomes. A few years after the 
Human Genome Reference sequence was announced, a new paradigm shift occurred in the 
process of DNA sequencing data production. The new DNA sequencing instruments and 
methods, known collectively as massively parallel sequencing (MPS), could process millions 
of sequence reads in parallel in a single instrument run compared to previous Sanger 
methods, and thereby significantly reduced the time, resources and costs to generate genome 
sequencing data. These techniques were also called ‘next generation’ sequencing 
technologies as they truly spurred a new direction to producing genomic data.2 
 
1.2 Massively Parallel Sequencing (MPS) technologies and 
analysis  
Several different technologies and companies emerged around the same timeframe, with 
different approaches to next generation sequencing3. Some of the early commercial 
contributors were Roche/454, Applied Biosystems SOLiD and Illumina, that differed based 
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on the sequencing chemistry used- pyrosequencing for Roche/454, ligation-based sequencing 
for SOLiD and polymerase-based sequencing-by-synthesis for Illumina. Amongst these, 
Illumina emerged as a market leader in terms of maintaining a reasonable cost of sequencing 
per Gb of data as well as the accuracy and applicability of the data generated. Currently, 
Illumina’s platform is the most widely used in the field. 
 
1.2.1 Steps to generate MPS data  
There are three main steps that are involved in generating MPS data. The first and foremost 
step is library production. This involves shearing and fragmenting genomic DNA, 
enzymatically polishing the fragment ends, and ligating known sequence adapters onto the 
fragment ends. These adapters may also carry bar coded DNA identifiers or indexes to permit 
downstream pooling of samples. The next step involves attaching these adapter-ligated 
library sequences onto a solid surface with complementary adapter sequences, and 
enzymatically amplifying the fragments. Fragment amplification is needed to provide 
sufficient signal during the sequencing reaction for on-instrument detection. Similarly, 
libraries for generating RNA-Seq data also can be prepared for MPS, first by conversion of 
the RNA to DNA using reverse transcriptase, followed by adapter ligation and surface 
amplification. The data resulting from RNA-Seq can be analyzed to determine digital 
expression values for genes in a given tissue or tumor. The last step is sequence data 
generation by reading the signals produced from the stepwise sequencing process that occurs 
at each amplified fragment population. This process involves detecting the identity of each 
nucleotide base that is added by DNA polymerase onto the fragments in each amplified 
library fragment cluster, obtained from differential label detection in certain instruments or 
by the sequential addition of each nucleotide reagent being coupled with a subsequent 
detection step that follows each nucleotide addition. Because this sequencing process takes 
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place on the solid support, for hundreds of millions to billions of fragment clusters being 
sequenced in parallel, the technology is called ‘massively parallel’ sequencing. The read 
length for most commonly used MPS technologies is relatively shorter (100-300bp) than 
traditional Sanger sequencing read lengths (800bp). This fact, coupled with the high 
throughput approach to sequencing enabled by MPS, requires analysis of the resulting reads 
by in silico alignment  to a fixed reference genome, followed by variant detection. In turn, the 
requisite sampling level or “coverage” needed to sequence genomes and obtain high 
confidence variant calling is nearly triple that of Sanger sequencing coverage levels (30-fold 
or higher coverage by MPS versus 8-10 fold coverage by Sanger). Additionally, the more 
compute-intensive nature of analyzing MPS data sets for genomes as large as the human 
(3Bbp), means that these large data sets require carefully constructed and validated analytical 
pipelines.   
 
MPS can be used to either sequence the entire genome (whole genome sequencing or WGS), 
or there are methods to select out genomic content from a whole genome library, such as the 
exons of known protein-coding genes (“exome”) or  a smaller number of selected genes or 
regions (“panel”). This is typically accomplished by an approach called “hybridization 
capture” sequencing or “exome” sequencing (in case of all protein coding genes), whereby 
synthetic probes designed to hybridize the exon sequences of protein coding genes are 
designed with covalently attached biotin molecules. By mixing such probes with the library 
fragments from a whole genome library under appropriate conditions, hybrids form between 
the synthetic probes and their cognate sequences in the library. These hybrids are 
subsequently captured by mixture with streptavidin-labeled magnetic beads, due to the 
binding of biotin by streptavidin, and subsequently the hybrids are isolated by applying a 
magnetic pull-down to isolate them from the remaining mixture. After isolation, the captured 
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library fragments are denatured from the synthetic probes and sequenced by MPS. Since 
human exome sequencing targets only the exons, which make up about 1.5% of the genome, 
the attendant data production is less expensive, the reads are more readily interpreted for 
variants, and the depth of coverage obtained can be higher and therefore more sensitive than 
compared to whole genome sequencing. 
 
1.2.2 Analysis of MPS data  
The sequence read alignment step is most often preceded by quality control of raw 
sequencing data and data preprocessing steps such as trimming of adapter sequence data from 
the reads. The quality control procedure can inform about any GC bias in the sequencing 
experiment by analyzing the GC content distribution, as well as any inconsistencies in the 
experiment by determining the read length distribution.  
 
While smaller, less complex genomes (viral or bacterial) can be assembled from the resulting 
short read MPS data using specific assembly algorithms, larger complex genomes like the 
human require alignment of short sequencing reads to the reference genome as a first step 
toward data analysis. In genomes such as human, mapping the reads to the reference genome 
is further complicated by not-yet-completed gaps in the reference genome or by differences 
between the reference and the genome being studied, including structural variants 
(chromosomal inversions, deletions, and translocations). Additionally, 48% of the human 
genome consists of repetitive elements that complicate accurate mapping of short reads due 
to multiple mapping likelihood at many regions in the genome.  
 
The post alignment processing involves data recalibration to mark and/or remove duplicates, 
and recalculation of quality scores after adjusting for local misalignments. Duplicate 
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sequencing reads may arise due to preferential enzymatic amplification of DNA fragments by 
the polymerase, especially when there are differences in the length of library fragments 
(shorter fragments are amplified preferentially) or differences in G-C content (more skewed 
A-T/G-C ratios amplify poorly). Such duplicates are reduced to a single read representative 
by de-duplicating software to avoid misrepresentation of copy number altered regions or to 
propagate PCR errors. To identify focal structural variants i.e. small insertions or deletions, 
the read data require a realignment and base quality score recalibration (BQSR) process to 
enhance their detection by variant calling software programs. 
 
After mapping and post-processing of the aligned reads to the reference genome, variant 
calling algorithms identify mutations in the sequenced DNA compared to the reference. This 
includes detection of several different types of variants such as single nucleotide variants 
(SNVs), focal insertions and deletions (indels), and copy number variants.  
 
One of the major prerequisites for successful detection of high quality variants is adequate 
sequence read data coverage of the genome or exome, which ensures sufficient depth on a 
given region of interest has been achieved to give statistical confidence of any variant 
identified therein. Also, filtering of discordant reads, such as those with multiple mismatches 
above a set threshold avoids sequencing errors being called as variants. Finally, variants 
called in aligned reads due to known false positivity contributors are often removed using 
statistical filters, such as variants found at the ends of reads where data quality is generally 
lower or variants called with reads only originating from single read orientation. 
 
The variant list is then annotated to determine the protein level effect of the peptide changes 
and to assess the functional significance of the predicted variants. The pathogenicity of 
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variants are then evaluated. Some commonly used tools to annotate and predict functional 
impact include Variant Effect Predictor (VEP)4,5, SIFT6,7, CHASM8, PolyPhen-29, 
MutationAssessor10, and ParsSNP4911. The mutation calls can be classified into different 
types depending on their effect on the resulting protein sequence such as - a) Missense 
(nonsynonymous) mutation, where a single amino acid  changes to another amino acid b) 
Nonsense mutation: where the point mutation changes an amino acid to a STOP codon 
resulting in premature termination of translation c)  Silent (synonymous) mutation: where the 
resulting mutation does not change an amino acid d) Frameshift mutation: these include 
insertion or deletion of a number of bases such that the frame of translation changes, leading 
to a completely new amino acid sequence and/or introducing a premature STOP codon, e) 
stopgain mutation, which eliminates the wildtype stop codon, resulting in a longer protein 
sequence. Furthermore, these mutations could either lead to “loss of function” of the protein 
or “gain of function”, either of which may be equally important. 
 
1.3 Cancer genome sequencing 
1.3.1  Large scale tumor genome sequencing projects 
As MPS technologies have attained widespread use and expanding application to multiple 
experimental aspects of biomedical research, their application to cancer genome 
characterization and discovery of new cancer genes in the research setting has been profound.   
 
The first MPS-based cancer genome was sequenced and reported by Ley et al12 in 2008. 
Single patient cancer genome sequencing studies such as this study also highlighted the 
importance of sequencing the patient’s normal genome in addition to the tumor genome13, as 
a means of distinguishing inherited (“germline”) alterations from those acquired in and 
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thereby specific to, the cancer genome (“somatic”). These initial small studies were 
accomplished by WGS and were quite expensive at the time, but as the cost of generating 
MPS data decreased, large-scale projects to discover and catalogue cancers were initiated and 
resulted in data generation and analysis from thousands of adult and pediatric cancers. For 
example, large scale sequencing efforts have been completed by several international 
consortia, such as The Cancer Genome Atlas (TCGA)14, International Cancer Genome 
Consortium (ICGC)15, Pediatric Cancer Genome Project (PCGP) and Pan Cancer Analysis of 
Whole Genomes (PCAWG). Due to the advances in MPS technologies and analytical 
approaches, it was possible to sequence  and identify the full range of somatic alterations in 
the genome, including single nucleotide variations, insertions and deletions, copy number 
variations, and large genomic rearrangements such as translocations, inversions, and other 
complex structural rearrangements16. 
 
In addition to defining the genomic landscape of thousands of cancer genomes across many 
disease types, these projects revealed the heterogeneity of mutational burden across cancer 
types (Figure 1.1). A broad spectrum of mutational frequencies is observed between, for 
example, carcinogen driven tumors such as tobacco smoking-associated lung cancers and  
UV radiation-driven melanomas which show the highest mutational burden, versus 
hematological tumors that have the lowest  mutational load.  
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Figure 1.1 Mutational heterogeneity of cancer. Figure originally published in Lawrence et. 
al.17 "Each dot corresponds to a tumor–normal pair, with vertical position indicating the 
total frequency of somatic mutations in the exome. Tumor types are ordered by their median 
somatic mutation frequency, with the lowest frequencies (left) found in hematological and 
pediatric tumors, and the highest (right) in tumors induced by carcinogens such as tobacco 
smoke and ultraviolet light. Mutation frequencies vary more than 1,000-fold between lowest 
and highest across different cancers and also within several tumor types. The bottom panel 
shows the relative proportions of the six different possible base-pair substitutions, as 
indicated in the legend on the left." 17  
 
Also, the large scale detailed analysis of the patient cohorts has led to findings about driver 
genes, driver mutations and passenger mutations, including the identification of significantly 
mutated genes (SMGs) occurring within specific tissue sites, as well as across multiple cancer 
types. These characterizations of genetic alterations have helped in substantially advancing 
our understanding of cancer genomes, especially as the data are integrated with RNAseq, 
methylation and other omics data types produced concurrently.  
 
By capturing even low abundance aberrations in clonal populations using MPS, these studies 
have also highlighted that even individual tumor types can have substantial genomic 
heterogeneity. It was found that even though there were SMGs seen across patient cohorts, at 
an individual patient level, the patterns and combinations of mutations that led to 
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development of cancer were different. This complexity further underscored the need to 
sequence each patient’s genome, due to the level of detail needed to discern and characterize 
the individual disease.   
 
1.3.2  Cancer genomics based treatments      
Coincident with our ability to sequence cancer DNA has been the development of new 
classes of cancer therapies that are developed to address specific cancer driver gene 
alterations. Initially, these were therapies such as Imatinib that targeted the protein fusion 
product of the BCR-ABL gene fusion, or Herceptin that targeted HER2 amplified breast 
cancers, both of which are interpretable without the need for DNA sequencing. Over time due 
to enhanced discovery offered by MPS-based analysis, we have now ascertained that cancer 
genes can be mutated in different tissue sites, such as BRAF mutations in melanomas, lung 
cancers, and brain cancers. This new realization has shifted diagnostic applications of MPS18 
from single gene mutation testing (often accomplished by PCR and Sanger sequencing) to 
multi-gene panel assays capable of surveying the many possible genes that may be mutated 
and may offer treatment decision-supporting evidence to physicians. Gene panel testing is 
also favored because it is cost effective and less time consuming to analyze the resulting data. 
It also offers a high rate of sensitivity to detect mutations in tumor DNA, which often has 
different amounts of normal cells interspersed that can decrease sensitivity, since it is 
possible to achieve fairly high coverage (300-500x) at the regions of interest.  
 
Due to unprecedented leaps in our understanding of cancer development powered by large 
scale sequencing of cancer samples, genomics based treatments have allowed the field of 
therapeutics move away from a ‘one size fits all’ approach to one that is more personalized to 
 
 
 10 
the patient’s genome. Concurrently, advances in molecular drug development and targeted 
therapies have enabled the transition of genomic assays into clinical use in patients with 
cancer19. 
 
Cancer genomics based assays have introduced a new era of molecular pathology and 
personalized, or “precision” medicine. By interpreting genomic information in light of  
targeted therapies, it is possible to identify additional cancer patients who might benefit.   
 
An emerging use of cancer genomics data is in predicting responses from new classes of 
cancer drugs known broadly as immunotherapy or immune checkpoint blockade therapy. In 
particular, cancer patients who have responses to immune checkpoint blockade therapies have 
been characterized by MPS as having an elevated mutational load or tumor mutation burden 
(TMB). By coupling our understanding of the impact of high TMB, namely the encoding of 
new protein sequences, that are unique to the cancer cells, with the potential impact on the 
adaptive immune system that would identify these novel proteins/peptides as ‘non-self’, one 
can predict that the response to immune checkpoint therapy is due to high numbers of tumor-
specific mutant antigens (neoantigens) being presented to the immune system on these cancer 
cells. 
 
1.4  Cancer Immunotherapy 
1.4.1 Tumor antigens 
In the late twentieth century, the immune-focused therapies for cancer that were postulated 
and tested did not deliver much clinical benefit, resulting in a diminution of enthusiasm for 
such therapeutic approaches. These studies were based on the hypothesis that due to the 
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aberrations in the cancer genomes, unique  peptides are presented on the cancer cells by the 
major histocompatibility complex (MHC) molecules which are then recognized by the 
Cytotoxic T lymphocytes (CTL)20,21. The altered peptides either could be normal 
differentiation antigens or aberrantly expressed normal proteins that are overexpressed in 
tumor cells versus the normal cells (tumor-associated antigens; TAAs), or those resulting 
from either oncogenic viral proteins or mutations unique to the tumor (tumor-specific 
antigens/neoantigens; TSAs).  
 
Tumor Associated antigens arise from non-mutated self proteins and are aberrantly expressed 
in tumor cells. One such type of self-differentiation antigens are the cancer–testis antigens 
(CTAs) that are present in immune-privileged normal cells but also are selectively presented 
to the immune system by tumor cells. These are not expressed in normal tissues except for 
testis, fetal ovaries, and trophoblasts but are also expressed in varying tumor types22. 
Melanoma Associated Antigen-1 (MAGE-1) was the first identified CTA which was 
discovered in 199123 using autologous cytotoxic T lymphocytes and autologous tumor 
mRNA. Another type of self-antigen is derived from non-mutated melanocyte lineage-
specific antigens, which include Melan-A/MART-1, gp100, and tyrosinase. These antigens 
usually have tissue specific expression and have been found to exhibit some level of enriched 
expression in various cancers. Since TAAs are also present in the normal cells, there is a risk 
of autoimmunity and the use of tumor-associated antigens as therapeutic targets can lead to 
normal tissue destruction and toxicity. 
   
TSAs are antigens arising from somatic changes in the tumor acquired during cancer 
initiation and progression, resulting in unique peptide sequences and are not seen in the 
normal cells.  Since these peptides are specifically presented in the tumor cells, they are likely 
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to be less susceptible to mechanisms of immunological tolerance. Early works on mouse 
models from the lab of Thierry Boon24 identified the first neoantigen resulting from a point 
mutation in the P91A gene in a mutagenized mouse tumor. A few years later, Hans Schreiber 
and colleagues25,26 demonstrated that tumor-specific mutations could result in immunogenic 
tumor-specific neoantigens, and demonstrated in vivo tumor rejection based on T cells 
targeting highly immunogenic, primary UV–induced mouse tumors. Another group 
demonstrated an autologous antibody-based method to clone and identify different human 
TSAs27.  All of these efforts paved the way for harnessing the power of antigens - TAAs or 
TSAs and showed an increasing evidence that the tumor antigenome was associated with a 
combination of these antigens. However, historically targeting TSAs was more laborious and 
challenging as the therapeutic strategies are specific to individual patients. As a result, the 
focus was primarily on targeting the TAAs or shared antigens that are not tumor-specific but 
expressed on large groups of cancers. 
 
1.4.2 Pre-MPS identification of tumor antigens 
Several approaches were developed to detect potential antigens that could be used for cancer 
immunotherapy28,29. Traditionally, reverse-transcription-polymerase chain reaction (RT-PCR) 
and real-time PCR (RQ-PCR) were used to detect expression of TAAs for a range of solid 
and haematological malignancies but these assays were used to limited to tumor antigens 
which had already been discovered. Another approach called Representational Difference 
Analysis (RDA) was developed to identify the CTAs such as the MAGE family of antigens30. 
Briefly, this technology uses subtractive hybridization to PCR-mediated kinetic enrichment to 
detect the differences between RNA sequences from the normal tissue (driver) and a tumor 
sample (tester). 
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In 1995, Sahin et al27 developed a method of Serological analysis of tumor antigens by 
Recombinant cDNA Expression cloning (SEREX). This method provided a base for high 
throughput screening of several TAAs, and was used widely to screen for plethora of antigens 
(> 2000) (http://www.licr.org/D_programs/d4a1i_SEREX.php) across different types of solid 
tumors as well as haematological malignancies. One example is NY-ESO-1, which is 
probably one of the most immunogenic CTAs discovered to date. It elicits specific CD4+ as 
well as CD8+ T-cell mediated immune responses in patients with solid tumors. SEREX starts 
with the construction of a cDNA library from freshly isolated tumor cells, which is expressed 
recombinantly. Thereafter, recombinant proteins are transferred onto membranes and 
screened with diluted serum of the same patient. TAAs are identified by their reactivity with 
IgG antibodies present in the patient's serum. Though several antigens can be screened 
together, one of the most laborious step in the SEREX approach is the construction 
expression libraries. This approach also does not detect post-translational modifications. 
 
Another approach known as serological proteome analysis (SERPA)31 combined proteomics 
approaches for the purpose of separating proteins and the serological screening with human 
serum antibodies. It involves using the proteomics workflow for an effective separation on 2-
DE gels for proteins that were extracted from primary tumors or cell lines, followed by an 
identification by Mass Spectrometry (MS). Unlike SEREX, this does not depend on 
recombinant expression of proteins, and thus can also screen for tumor specific post-
translational modifications of proteins. 
 
Besides using the Mass Spectrometry (MS) based approaches, cDNA microarrays also have 
been used to compare the differential expression of tumor antigens from normal tissues and 
cancer tissues. Most of these approaches focused on the identification and validation of 
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TAAs. Although there were attempts in the mid 1980’s to identify tumor-specific mutant 
antigens (TSMAs) from cancers, these efforts were painstaking and not scalable using Sanger 
sequencing approaches.   
 
 
1.4.3 Neoantigens  
Many early studies demonstrated the importance of TSMAs or neoantigens as significant 
targets of antitumor immune responses32,33,34. However, screening for neoantigens before the 
sequencing of the human genome and the advent of MPS, was a daunting task with very little 
gain since it required the identification of mutations and HLA typing to be done for each 
patient. Thus, much of the focus for cancer immunotherapy based treatments in the early 
2000s was on targeting and evaluation of TAAs and CTAs, as described. 
 
With the completion of the first sequence of the human reference genome in 2004, early 
efforts to design PCR primers and amplify and Sanger sequence DNA from cancers to 
identify somatic mutations emerged, making it clear that cancer cells, especially in some 
tissue sites, carry multiple mutations in their genes. From these studies, a visionary 
suggestion emerged35. In 2008, Allison and Vogelstein36 proposed that all cancers have 
mutations that could form neoantigens by conducting an in silico analyses of exome-
sequencing data from breast and colorectal cancers. While the study lacked any experimental 
validation of the predicted neoantigens, they profiled several mutations that were predicted to 
form tumor-specific mutant antigens for CD8+ T cells, exhibiting the ability of the cancer 
genome to form epitopes recognizable by the immune system due to accumulated genetic 
changes. 
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In 2012, two independent groups demonstrated neoantigen prediction approaches based on 
MPS somatic variant identification, including how the identified variants, when considered in 
the context of MHC binding affinity, could predict tumor specific neoantigens in murine 
sarcoma models37,38. By using the resulting set of potential neoantigens to query T cell 
reactivity, the predictions were validated. It was further demonstrated that these validated 
neoantigens were the same epitopes recognized by anti-PD1 and anti-CTLA439 immune 
checkpoint blockade therapies and that peptide vaccines comprised of the peptide 
neoantigens provided either prophylactic or therapeutic efficacy. Several other studies have 
also characterized neoantigens as being derived from somatically mutated genes40–43, and 
have shown that they can be recognized by T-cells. 
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Figure 1.2: An overview of self vs non-self paradigm for neoantigen vaccines: Figure 
originally published in Houghton and Guevara-Patiño44 - “Initial studies demonstrated that 
host CD8+ T cells respond to a self peptide presented by MHC-I molecules on tumor cells. 
The wild-type self peptide ITDQVPFSV is unable to trigger an immune response against the 
tumor cells either due to being a weak binder or being eliminated due to the process of self-
tolerance. The mutated peptide ITDQVPFSV results in a neoantigen which is highly stable 
and activates the host T cells. Once the CD8+ T cells are activated, they are competent to 
recognize and kill host tumor cells presenting the non-mutated self peptide.”    
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These landmark studies by Matsushita et al37 and Castle et al38  introduced  “reverse 
immunology approaches”  for identification of neoantigens and opened new avenues to tailor 
personalized treatments using TSMAs by exploiting the full mutanome of a patient. Briefly, 
in these studies the analysis pipelines combined genomic, bioinformatic and immunological 
methods45 to determine the set of most immunogenic neoantigens (Figure 1.2). Starting with 
the set of somatic variants identified using MPS, the amino acid changes are translated, and 
representative short peptides are generated that window through the variant amino acid, to 
place it at locations from beginning to end in the peptide, and its ability to bind to the MHC is 
determined using epitope prediction algorithms. The normal exome data are analyzed through 
a specific algorithm to identify the HLA haplotypes used for this evaluation. The two most 
critical components of this approach are the identification of high quality somatic mutations 
using MPS data as well as accurate prediction of the peptide binding to the MHC alleles. As 
mentioned in previous sections, depth of coverage by MPS sequencing reads from the tumor 
is an important factor for detection of high confidence somatic variants. The coverage is also 
needed to correctly infer clonality of the mutation, based on the reads that identify the variant 
and their representation at the variant site of germline vs. mutant. This type of analysis is 
needed to partition variants in the founder clone (those present in every cell) from those in 
subclonal populations (not present in every cell, by inference). From an immunotherapy 
perspective, targeting neoantigens that associate with the  founder clone produces an immune 
response that targets all cancer cells rather than only selected cells (i.e. those carrying  
subclonal mutations/neoantigens). Another aspect that determines the immunogenicity of the 
selected neoantigen is its ability to bind to the MHC molecule. Typical, peptides of lengths 
8–11 amino acids bind to MHC Class I molecules that present them to cytotoxic CD8+ T 
cells and peptides of longer lengths, typically between 11–30 amino acids, bind to MHC 
Class II molecules and are presented to CD4+ T cells. Predicting the binding affinity of a 
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large number of peptides arising from somatic mutations to the MHC alleles is onerous, and 
therefore has now been streamlined by various computational pipelines.  
 
1.4.4 Computational methods for peptide binding prediction to MHC 
alleles 
One critical component for the correct prediction of antigen binding to MHC alleles is 
obtaining the high-resolution HLA allelotype of the patient. Traditionally, PCR and Sanger 
sequencing-based clinical assays have been used to derive patient-specific HLA haplotypes. 
More recently, several in silico based tools have been developed that can predict the correct 
HLA haplotypes at up to a 99% accuracy for four-digit resolution46. These tools either use an 
alignment-based approach or an assembly-based approach from MPS read data. Alignment-
based HLA typing softwares such as PolySolver47 and Optitype48 align the read to the 
reference HLA sequences (genomic, exomic or transcriptomic) and use probabilistic 
modeling to infer correct HLA types. Assembly-based approaches such as ATHLATES49 and 
HLAminer50 involve de novo assembly of MPS read data  into contigs which are then aligned 
to the reference sequences of known HLA alleles to resolve the haplotypes. 
 
Experimental screening of large numbers of predicted neoantigen  candidates is an expensive 
and time-consuming endeavor. As MPS technologies have become more widely used for 
cancer immunogenomics evaluations51, computational methods to determine accurate binding 
prediction of the peptides to the MHC molecules (Class I or Class II)  have also evolved52. 
 
Several computational tools of this type, including BIMAS53, SYFPEITHI54, and 
RANKPEP55, rely on position-specific scoring matrices (PSSMs). These softwares make 
predictions of MHC-peptide binding based on the position of amino acids in the putative neo-
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peptide as it sits in the binding cleft of the protein, such as at the anchor position, unusual 
anchor position, and auxiliary anchor position. The binding potential of different peptides is 
based on identification of allele-specific motifs and by taking into account the positions of the 
amino acids - optimally preferred positions of amino acids scored higher over the undesirably 
placed amino acids in calculating the binding affinity.  
 
After the widespread adoption of MPS, the number of MHC alleles (specifically HLA alleles) 
that were identified also increased exponentially, and it became necessary to improve MHC 
binding prediction methods. One major shortcoming of the PSSM based approaches was the 
inability to correctly account for the interrelationships between different MHC cleft binding 
positions. This was overcome by using more complex, machine learning-based approaches to 
establish models for the different types of binding site interactions, and thereby determine 
patterns of binding based on existing datasets. These machine learning-based methods are 
broadly divided as follows:  
a) Artificial neural networks (ANN): These methods are trained using a set of 
experimentally derived binding affinity measurements for different class I and II  
HLA haplotypes. One of the first software programs developed using ANN-based 
modeling was NetMHC56,57. The accuracy of this method largely depends on the 
quality and size of the training set, and hence it is more accurate for predicting MHC-
peptide binding potential for the more common MHC alleles due to the relative 
abundance of binding data for common haplotypes. Since rare HLA alleles are not as 
well supported by experimental binding data, more accurate algorithms were 
developed to calculate the peptide binding affinity potential to such alleles. 
NetMHCpan57,58 and Pickpocket59 are two such pan-specific algorithms that were 
trained by expanding the original training set to include data from other species, as 
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well as extrapolating the affinities for rare alleles from known binding affinities. 
Incorporating these additional parameters subsequently led to improved accuracy for 
rare MHC alleles. Another ANN-based approach, applied in NetMHCCons60, 
combines multiple tools to obtain more reliable binding affinity predictions and uses 
consensus to compensate for the strengths and weaknesses of different algorithms.  
Further improvements to neural network-based methods have resulted in tools such as 
MHCflurry61 and MHCnuggets62. 
 
b) Stabilized Matrix Method (SMM): These methods use protein position-weight 
matrices to model the binding process. Examples include SMM63 and SMMPMBEC64 
that use quantitative matrices  not only for predicting binding of peptide to MHC class 
I molecules, but also for predicting both the transport of the peptide by transporter 
associated with antigen processing (TAP), and proteasomal cleavage of protein 
sequence.  
 
Though most of the efforts have been focused on developing methods for binding predictions 
to MHC Class I molecules, some of these softwares such as NetMHCIIpan65 and 
MHCnuggets62 , extend support for Class II predictions as well. 
 
Once a list of strong binding peptide candidates is determined using the aforementioned  
methods, the peptides are validated in vitro to determine their binding potential and/or their T 
cell based immune response using different assays. These include MHC Peptide binding 
assays that assess peptides based on their competitive binding to the MHC molecules,  
ELISPOT/ELISA that measures IFNγ production, flow cytometry-based Peptide–MHC 
tetramer/dextramer assays, or combinations of any of these. 
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The selected neoantigen peptides could be further employed to study different aspects of 
cancer immunology and immunotherapy. One type of cancer immunotherapy, called 
‘immune checkpoint blockade’ acts by removing immune suppression by binding to cell 
surface markers that induce T cell exhaustion. Several groups have studied the correlation 
between  tumor mutation burden (TMB) or neoantigen load as a predictor of immune 
checkpoint blockade response likelihood66,67, and have shown a strong association between 
somatic mutation burden and  clinical response in patients treated with anti-CTLA4 or anti-
PD1. While checkpoint blockade therapies predominately provide a tumor-specific immune 
response, there could be often adverse reactions because these therapies target native immune 
molecules such as CTLA-4, PD-1 and PD-L1. Another type of immunotherapy-based 
approach called ‘personalized vaccines’ is more tumor specific since these therapies target 
neoantigens or TSMAs, that result from somatic alterations. As these therapies are tissue 
specific, they yield fewer off-target effects and hence, lowered likelihood of severe adverse 
events. To administer such vaccines, different types of vaccine platforms have been tested 
and employed in different settings, as explained in the next section. 
 
1.4.5 Vaccine platforms for neoantigen-based therapy 
Once a list of strong binding neoantigens has been identified and validated in vitro,  a vaccine 
platform is required for therapeutic administration into the patient. Multiple vaccine 
platforms are being explored for personalized cancer vaccines, some of which are elucidated 
below68: 
a) DNA vaccines: This vaccine platform involves constructing a circularized DNA insert  
carrying one or more encoded neoantigenic peptide sequences and inserting the 
construct into a DNA vector. One important consideration in the design of these 
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vaccines is the order of neoantigenic sequences along with spacer sequences such that 
no new strong binding junctional epitope is encoded by the resulting sequence. The 
DNA vaccine platform is relatively inexpensive to produce as a GMP-grade construct 
because DNA synthesis is rapid, automated and inexpensive, and DNA sequencing 
can be used to verify the final sequence of the construct prior to administration. These 
attributes also would enable rapid scalability of DNA vaccines for precision medicine 
applications in cancer therapy, if warranted.  
 
b) Peptide-based vaccines: This vaccine platform involves the direct administration (by 
intramuscular injection) of synthetic neoantigenic peptide cocktails suspended in 
administrative adjuvant solution. A recent publication described the use of this 
vaccine platform using synthetic long 15–30-mer peptides suspended in poly-ICLC 
(Hiltonol)69 wherein six melanoma patients were immunized with up to 20 distinct 
neoantigenic peptides  predicted to bind to MHC class I molecules. Peptide vaccines 
are relatively more expensive to generate due to the requirement of synthesizing the 
peptides under GMP conditions, and don't always solubilize well with one another, so 
often several cocktails must be made in the adjuvant and administered separately. 
However, peptide based vaccines are easy to characterize, and straightforward to 
synthesize, making the platform relatively scalable.  
 
c) RNA-based vaccines: These vaccines are conceptually similar to DNA and peptide 
vaccines wherein synthetic RNAs encode the various predicted neoantigenic peptides 
evaluated from the patient’s tumor. One of the main advantages of using this approach 
is that by using mRNA as the vaccine, it can be readily translated once in the cell in 
order to induce antigen-specific T cell immune responses. However, stability of RNA 
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molecules and appropriate processing and presentation by antigen presenting cells 
remains one of the major challenges of this vaccination strategy. Sahin et al70 used 
this vaccine platform to immunize 13 patients with advanced cutaneous melanoma. 
Synthetic RNAs encoding five linker-connected 27-mer peptides were formulated 
based on neoantigen predictions of both MHC Class I and Class II binders. In this 
study, 60% of the candidate neoepitopes elicited some sort of immune response, and 
the majority of T cell responses were CD4+, directed against MHC class II-restricted 
antigens. 
 
d) Dendritic cell (DC) based vaccines: These vaccines involve collection of circulating 
blood, from which isolated dendritic cells are matured ex vivo in the presence of 
neoantigenic peptides. The matured dendritic cells are infused into the same patient. A 
recent melanoma trial by Carreno et al71 used this strategy in three melanoma patients, 
who had been pretreated with ipilimumab. These patients were vaccinated with DC 
loaded with about 7 neoantigenic derived from each patient’s tumor. Only a subset of 
the candidates showed existing or de novo immune responses, thus underscoring the 
difficulties of predicting peptides that will be processed and presented. 
 
Using tumor specific neoantigens, these vaccine platforms and the associated trials have 
shown that there are few, if any, severe adverse events and little cross-reactivity to the wild 
type (normal) peptide. These initial clinical trials69,70,71 show promising results about the 
safety and tolerance of vaccines that employ neoantigens for cancer therapy. Two of these 
studies further treated patients that had a recurrent/progressive disease with checkpoint 
blockade therapy (anti-PD1)72 and clinically significant disease regression was reported, 
 
 
 24 
showing value in the use of combinations such as neoantigen-based vaccines with immune 
checkpoint blockade. 
 
Another type of therapy that employs the use of neoantigens, though not directly in the form 
of vaccines, is adoptive T cell transfer therapy (ACT). This type of therapy pioneered by 
Rosenberg et al. involves removing tumor-specific T cells, either from peripheral blood or the 
resected tumor, and expanding them ex vivo which allows them to regain their cytotoxic 
function, such that when they are transferred back into the patient, they can drive tumor 
elimination. ACT, when used on patients with solid tumors41,73 showed measurable T-cell 
specific immune responses against neoantigens. Following treatment with ACT in pilot trials, 
it has been shown74 that 40% of treated patients experienced complete regressions of all 
measurable lesions for at least five years. While ACT provides another tumor-specific 
approach for treatment with fewer side effects, these therapies are costly due to the need for 
ex vivo expansion of patient-specific T cells for each patient. 
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Figure 1.3:  Overview of personalized vaccine design process: Figure originally published 
in Liu and Mardis45. Tumor tissue and blood normal samples are extracted from the patient 
and  exome and RNA sequencing is performed, followed by read alignment and variant 
calling algorithms to identify and confirm expression of somatic mutations. This input is used 
to determine strong binding neoantigens by using MHC class I & class II epitope prediction 
algorithms. The selected set of high quality neoantigens are further prioritized by ELISPOT 
and peptide binding assays, before being incorporated in a vaccine.     
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1.5  Development and improvement of sequencing 
methods for neoantigen characterization       
Methods to more accurately identify which tumor-specific mutant peptides (neoantigens) can 
elicit anti-tumor T cell immunity are needed if the pursuit of personalized vaccine therapy 
and adoptive T cell therapy continues to advance in medical care of cancer patients.  
Although the cost-related barriers to producing somatic mutations from MPS data sets have 
fallen away with new instrumentation and analytical improvements, barriers to facile use of 
computational analyses that yield neoantigen predictions still remain and, if not addressed, 
diminish the widespread adoption of this approach to cancer treatment. Since the mutational 
repertoire of a typical cancer genome can vary anywhere from 50 to 500+ mutations, there 
was a need for a strategy that integrates somatic mutation calls from MPS data, identifies the 
neoantigens in the context of the patient’s HLA alleles, and parses out a list of optimal 
peptides for downstream testing, as illustrated in Figure 1.3. Chapter 2 describes such a 
genome-guided in silico approach to identifying tumor neoantigens that starts with a simple 
list of somatic nonsynonymous point mutations from which it predicts high affinity 
neoantigens  refined by sequencing coverage and gene expression data. Such a pipeline has 
been utilized in several first-in-human clinical trials of patient-specific vaccines using 
different vaccine platforms, including DNA-based and dendritic cell-based vaccines. We 
have further refined the approach to neoantigen prediction from that presented in Chapter 2 
by testing the impact of regional-specific adjustments to peptide sequences entering 
consideration for MHC binding affinity predictions. Namely, this approach accounts for the 
individual-specific variants in the germline, as well as the adjacent somatic alterations that 
occur most frequently in high mutation load tumors, proximal to the variant being evaluated 
for neoantigen binding. This correction in germline proximal variants is often not done 
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because there is an assumption that the human reference genome is representative of the 
patient’s inherited variants, some of which may change amino acid sequence in the resulting 
peptide. All of these assumptions can  lead to incorrect determination of neoantigenic peptide 
sequences and to incorrect binding affinities as a consequence. Chapter 3 describes our 
results from studying the effect of proximal sequence correction on the calculated binding 
affinities and suggests a corrective approach that, in some cases, dramatically impacts the 
calculated binding affinity. 
   
We also recognized that neoantigen vaccine therapies may be applied in cancers without high 
mutational loads, and that the challenges of identifying a sufficient number of neoantigens to 
construct a vaccine might be challenging in this circumstance.  Hence, we sought to increase 
the numbers of variants that could be evaluated for MHC binding by including rarer types of 
variants, including frameshift indel and gene fusions, into neoantigen prediction.  In addition, 
since there is evidence that MHC Class II binding neoantigens are appropriate to include in 
vaccines70, we also wanted to include these predictions into our established pipeline 
described in Chapter 2.  Chapter 4 describes a modular computational framework to facilitate 
each of the critical stages of neoantigen characterization. It integrates the information from 
Chapters 2 and 3 into a toolkit that enables neoantigen prediction from the breadth of somatic 
alterations including point mutations, insertions, deletions, and gene fusions. Furthermore, 
prioritization and selection of these neoantigens for non-informatics savvy users is provided 
through a graphical web-based interface. Lastly, this revised approach provides a 
functionality to determine the optimal order of selected neoantigen candidates in a DNA 
vector-based vaccine. 
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Chapter 2: pVAC-Seq: A genome-guided in 
silico approach to identifying tumor 
neoantigens 
 
 
Hundal, Jasreet et al. pVAC-Seq: A genome-guided in silico approach to identifying tumor 
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2.1 Introduction 
Cancer immunotherapy has gained significant momentum from recent clinical successes of 
checkpoint blockade inhibition. Massively parallel sequence analysis suggests a connection 
between mutational load and response to this class of therapy. Methods to identify which 
tumor-specific mutant peptides (neoantigens) can elicit anti-tumor T cell immunity are 
needed to improve predictions of checkpoint therapy response and to identify targets for 
vaccines and adoptive T cell therapies. Here, we present a flexible, streamlined 
computational workflow for identification of personalized Variant Antigens by Cancer 
Sequencing (pVAC-Seq) that integrates tumor mutation and expression data (DNA- and 
RNA-Seq). pVAC-Seq is available at https://github.com/griffithlab/pVAC-Seq. 
 
2.2 Background 
Boon et al. were the first to demonstrate that cancer-specific peptide/MHC class 1 complexes 
could be recognized by CD8+ T cells present in cancer patients75. Substantial evidence now 
suggests that anti-tumor T cells recognize tumor somatic mutations, translated as single 
amino acid substitutions, as ‘neoantigens’. These unique antigenic markers arise from 
numerous genetic changes, acquired somatically that are present exclusively in tumor 
(mutant) and not in normal (wild-type (WT)) cells76. Recent preclinical data indicate that 
these mutated proteins, upon processing and presentation in the context of MHC molecules 
expressed by antigen-presenting cells, can be recognized as ‘non-self’ by the immune system. 
Our previous work in murine sarcoma models was one of the first demonstrations of how 
somatic cancer mutations could be identified from massively parallel sequencing, and when 
considered in the context of MHC binding affinity, can predict tumor specific neoantigens38. 
A subsequent study further demonstrated that these neoantigens were the same epitopes 
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recognized by anti-PD1 and anti-CTLA4 checkpoint blockade therapies and that peptide 
vaccines comprising neoantigens could provide prophylactic effects. Several other studies 
have also characterized these neoantigens as being derived from somatically mutated genes in 
mouse 39 as well as in humans40–43, and have shown that they can be recognized by T cells. 
 
While checkpoint blockade therapies have achieved tremendous success in the clinic, patient-
specific vaccines still meet a clinical need in those patients that either do not respond, 
develop resistance, or cannot tolerate the associated side effects of checkpoint blockade 
drugs. The main paradigm behind the development of cancer vaccines rests on the 
assumption that if the immune system is stimulated to recognize neoantigens, it may be 
possible to elicit the selective destruction of tumor cells. Vaccines incorporate these 
neoantigen peptides with the aim of enhancing the immune system’s anti-tumor activity by 
selectively increasing the frequency of specific CD8+ T cells, and hence expanding the 
immune system’s ability to recognize and destroy cancerous cells. This process is dependent 
on the ability of these peptides to bind and be presented by HLA class I molecules, a critical 
step to inducing an immune response and activating CD8+ T cells77. 
 
As we move from vaccines targeting ‘shared’ tumor antigens to a more ‘personalized’ 
medicine approach, in silico strategies are needed to first identify, then determine which 
somatic alterations provide the optimal neoantigens for the vaccine design. Ideally, an 
optimal strategy would intake mutation calls from massively parallel sequencing data 
comparisons of tumor to normal DNA, identify the neoantigens in the context of the patient’s 
HLA alleles, and parse out a list of optimal peptides for downstream testing. At present, 
elements of this ideal strategy exist, but are not available as open source code to permit others 
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to adopt these methods into cancer care strategies. This manuscript describes one such 
approach, and provides a link to open source code for end users. 
 
For example, to optimize identification and selection of vaccine neoantigens, several in silico 
epitope binding prediction methods have been developed57,78–81. These methods employ 
various computational approaches such as Artificial Neural Networks (ANN) and Support 
Vector Machines (SVM) and are trained on binding to different HLA class I alleles to 
effectively identify putative T cell epitopes. 
 
There are also existing software tools (IEDB82, EpiBot83, EpiToolKit84 ) that compile the 
results generated from individual epitope prediction algorithms to improve the prediction 
accuracy with consensus methods or a unified final ranking. The current implementation of 
EpiToolKit (v2.0) also has the added functionality of incorporating sequencing variants in its 
Galaxy-like epitope prediction workflow (via its Polymorphic Epitope Prediction plugin). 
However, it does not incorporate sequence read coverage or gene expression information 
available from massively parallel sequencing datasets, nor can it compare the binding affinity 
of the peptide in the normal sample (WT) versus the tumor (mutant). Another multi-step 
workflow Epi-Seq85 uses only raw RNA-Seq tumor sample reads for variant calling and 
predicting tumor-specific expressed epitopes. 
 
We report herein an open source method called pVAC-Seq that we developed to address the 
critical need for a workflow that assimilates and leverages massively parallel DNA and RNA 
sequencing data to systematically identify and shortlist candidate neoantigen peptides from a 
tumor’s mutational repertoire that could potentially be used in a personalized vaccine after 
immunological screening. This automated analysis offers the functionality to compare and 
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differentiate the epitopes found in normal cells against the neoepitopes specifically present in 
tumor cells for use in personalized cancer vaccines, and the flexibility to work with any user-
specified list of somatic variants. Preliminary versions of this pipeline were applied in mouse 
models of cancer to identify expressed mutations in cancer cells and characterize tumor-
specific mutant peptides that drive T cell-mediated tumor rejection in mice with MCA-
induced sarcomas38,39 . More recently, we used this pipeline in a proof-of-concept trial in 
melanoma patients, to identify the neoantigen peptides for use in dendritic cell-based 
personalized vaccines71. 
 
2.3 Methods 
Our in silico automated pipeline for neoantigen prediction (pVAC-Seq) requires several types 
of data input from next-generation sequencing assays. First, the pVAC-Seq pipeline requires 
a list of non-synonymous mutations, identified by a somatic variant-calling pipeline. Second, 
this variant list must be annotated with amino acid changes and transcript sequences. Third, 
the pipeline requires the HLA haplotypes of the patient, which can be derived through 
clinical genotyping assays or in silico approaches. Having the above-mentioned required 
input data in-hand, pVAC-Seq implements three steps: performing epitope prediction, 
integrating sequencing-based information, and, lastly, filtering neoantigen candidates. The 
following paragraphs describe the analysis methodology from preparation of inputs to the 
selection of neoantigen vaccine candidates via pVAC-Seq (Figure 2.1). 
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Figure 2.1. Overview of the pipeline pVAC-Seq: This figure illustrates the methodological 
framework behind the pVAC-Seq pipeline. Starting with preparation of inputs, it consists of 
three main steps - epitope prediction, integration of sequencing information, and filtered 
candidate selection. 
 
 
 
2.3.1 Prepare input data: HLA typing, alignment, variant detection, and 
annotation 
As described above, pVAC-Seq relies on input generated from the analysis of massively 
parallel sequencing data that includes annotated nonsynonymous somatic variants that have 
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been ‘translated’ into mutant amino acid changes, as well as patient-specific HLA alleles. 
Importantly, these data can be obtained from any appropriate variant calling, and annotation 
pipeline and HLA typing approach. Here, we outline our preparatory steps to generate these 
input data71. Somatic variant analysis of exome sequencing datasets was performed using the 
Genome Modeling System (GMS)86 for alignment and variant calling. In brief, BWA 
(version 0.5.9)87 was used for alignment with default parameters, except that the number of 
threads was set to 4 (-t 4) for faster processing, and the quality threshold for read trimming to 
5 (-q 5). The resulting alignments were de-duplicated via Picard MarkDuplicates (version 
1.46) 88. 
 
In cases where clinically genotyped HLA haplotyping calls were not available, we used in 
silico HLA typing by HLAminer (version 1)50 or by Athlates49 . HLA typing was performed 
on the normal (peripheral blood mononuclear cells), rather than the tumor sample. Though 
the two software tools were >85% concordant in our test data (unpublished data), it is helpful 
to use both algorithms in order to break ties reported by HLAminer (see below). 
I. HLAminer for in silico HLA-typing using Whole Genome Sequencing (WGS) data: 
When predicting HLA class I alleles from WGS data, we used HLAminer in de novo 
sequence alignment mode89 by running the script HPTASRwgs_classI.sh, provided in 
the HLAminer download, with default parameters. (The download includes detailed 
instructions for customizing this script, and the scripts on which it depends, for the 
user’s computing environment.) For each of the three HLA loci, HLAminer reports 
predictions ranked in decreasing order by score, where ‘Prediction #1’ and ‘Prediction 
#2’ are the most likely alleles for a given locus. When ties were present for Prediction 
1 or Prediction 2, we used all tied predictions for downstream neoepitope prediction. 
However, it should be noted that most epitope prediction algorithms, including 
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NetMHC57,80 only work with an algorithm-specific subset of HLA alleles, so we are 
constrained to the set of NetMHC-compatible alleles. The current version NetMHC 
v3.4 supports 78 human alleles. 
 
II. Athlates for in silico HLA-typing using exome sequence data: We diverged from the 
recommended Athlates protocol at two points: (1) We performed the alignment step, 
in which exome sequence data from the normal tissue sample are aligned against 
reference HLA allele sequences present in the IMGT/HLA database90, using BWA 
with zero mismatches (params : bwa aln -e 0 -o 0 -n 0) instead of NovoAlign91 with 
one mismatch. (2) In the subsequent step, sequence reads that matched, for example, 
any HLA-A sequence from the database were extracted from the alignment using 
bedtools92 instead of Picard. This procedure is resource-intensive, and may require 
careful resource management. Athlates reports alleles that have a Hamming distance 
of at most 2 and meet several coverage requirements. Additionally, it reports ‘inferred 
allelic pairs’, which are identified by comparing each possible allelic pair to a longer 
list of candidate alleles using a Hamming distance-based score. We typically used the 
inferred allelic pair as input to subsequent steps in the neoepitope prediction pipeline. 
 
After alignments (and optional HLA typing) were completed, somatic mutation detection was 
performed using the following series of steps (1) Samtools 93,94 mpileup v0.1.16 was run with 
parameters ‘-A -B’ with default setting for the other parameters. These calls were filtered 
based on GMS ‘snp-filter v1’ and were retained if they met all of the following rules: (a) Site 
is greater than 10 bp from a predicted indel of quality 50 or greater; (b) The maximum 
mapping quality at the site is ≥40; (c) Fewer than three single-nucleotide variants (SNV) calls 
are present in a 10 bp window around the site; (d) The site is covered by at least three reads 
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and less than 1 × 109 reads; and (e) Consensus and SNP quality is ≥20. The filtered Samtools 
variant calls were intersected with those from Somatic Sniper95 version 1.0.2 (params: -F vcf 
q 1 -Q 15), and were further processed through the GMS ‘false-positive filter v1’ (params: --
bam-readcount-version 0.4 --bamreadcount-min-base-quality 15 --min-mapping-quality 40 --
min-somatic-score 40). This filter used the following criteria for retaining variants: (a) ≥1% 
of variant allele support must come from reads sequenced on each strand; (b) variants must 
have ≥5% Variant Allele Fraction (VAF); (c) more than four reads must support the variant; 
(d) the average relative distance of the variant from the start/end of reads must be greater than 
0.1; (e) the difference in mismatch quality sum between variant and reference reads must be 
less than 50; (f) the difference in mapping quality between variant and reference reads must 
be less than 30; (g) the difference in average supporting read length between variant and 
reference reads must be less than 25; (h) the average relative distance to the effective 3’ end 
of variant supporting reads must be at least 0.2; and (i) the variant must not be adjacent to 
five or more bases of the same nucleotide identity (for example, a homopolymer run of the 
same base). (2) VarScan Somatic version 2.2.696,97 was run with default parameters and the 
variant calls were filtered by GMS filter ‘varscan-high-confidence filter version v1’. The 
‘varscan-high-confidence v1’ filter employed the following rules to filter out variants: (a) P 
value (reported by Varscan) is greater than 0.07; (b) Normal VAF is greater than 5%; (c) 
Tumor VAF is less than 10%; or (d) less than two reads support the variant. The remaining 
variant calls were then processed through false-positive filter v1 (params: --bam-readcount-
version 0.4 --bamreadcount-min-base-quality 15) as described above. (3) Strelka version 
1.0.10 98(params: isSkipDepthFilters = 1). 
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Our GMS pipeline expects a matched normal sample for filtering out potentially rare 
germline variants. However, in the absence of a matched normal tissue, the dbSNP and 1000 
Genome databases could be used for filtering these variants. 
 
The consolidated list of somatic mutations identified from these different variant-callers was 
then annotated using our internal annotator as part of the GMS pipeline. This annotator 
leverages the functionality of the Ensembl database99 and Variant Effect Predictor (VEP)5. 
 
We wish to emphasize that any properly formatted list of annotated variants can be used as 
input to subsequent steps in the pipeline. From the annotated variants, there are two critical 
components that are needed for pVAC-Seq: amino acid change and transcript sequence. Even 
a single amino acid change in the transcript arising from missense mutations can alter the 
binding affinity of the resulting peptide with the HLA class I molecule and/or recognition by 
the T cell receptor. Larger insertions and deletions like those arising from frameshift and 
truncating mutations, splicing aberrations, gene fusions, and so on may also result in potential 
neoantigens. However, for this initial version of pVAC-Seq, we chose to focus our analysis 
on only missense mutations. 
 
One of the key features of our pipeline is the ability to compare the differences between the 
tumor and the normal peptides in terms of the peptide binding affinity. Additionally, it 
leverages RNA-Seq data to incorporate isoform-level expression information and to quickly 
cull variants that are not expressed in the tumor. To easily integrate RNA-Seq data, both 
transcript ID as well as the entire WT transcript amino acid sequence is needed as part of the 
annotated variant file. 
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2.3.2 Perform epitope prediction 
One of the key components of pVAC-Seq is predicting epitopes that result from mutations by 
calculating their binding affinity against the HLA class I molecule. This process involves the 
following steps for effectively preparing the input data as well as parsing the output (Figure 
2.2). 
 
Figure 2.2 Generation of peptide sequences and filtering predicted epitope candidates. a 
Amino acid FASTA sequence is built using 10 flanking amino acids on each side of the 
mutated amino acid. The preceding or succeeding 20 amino acids are taken if the mutation 
lies near the end or beginning of the transcript, respectively. b All predicted candidate 
peptides from epitope prediction software based on selected k-mer window size. c Only 
localized peptides (those containing the mutant amino acid) are considered to compare to 
WT counterpart. d The ‘best candidate’ (lowest MT binding score) per mutation is chosen 
across all specified k-mers and between all independent HLA allele types that were used as 
input 
 
Generate FASTA file of peptide sequences 
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Peptide sequences are a key input to the MHC binding prediction tool, and the existing 
process to efficiently compare the germline normal with the tumor is very onerous. To 
streamline the comparison, we first build a FASTA file that consists of two amino acid 
sequences per variant site: WT (normal) and mutant (tumor). The FASTA sequence is built 
using approximately eight to 10 flanking amino acids on each side of the mutated amino acid. 
However, if the mutation is towards the end or beginning of the transcript, then the preceding 
or succeeding 16 to 20 amino acids are taken, respectively, as needed, to build the FASTA 
sequence. Subsequently, a key file is created with the header (name and type of variant) and 
order of each FASTA sequence in the file. This is done to correlate the output with the name 
of the variant protein, as subsequent epitope prediction software strips off each FASTA 
header. 
 
Run epitope prediction software 
Previous studies100,101 have shown that allele-specific epitope prediction software, such as 
NetMHC, perform slightly better when compared to pan-specific methods such as 
NetMHCpan58,65,102 in case of well-characterized alleles due to availability of large amounts 
of training data. However, pan-specific methods could be beneficial in cases where there is 
limited peptide binding data for training, for arbitrary HLA molecules, or when predicting 
epitopes for non-human species. We do anticipate adding this support for additional 
softwares in upcoming versions of pVAC-Seq. To predict high affinity peptides that bind to 
the HLA class I molecule, currently only the standalone version of NetMHC v3.4 is 
supported. The input to this software is the HLA class I haplotype of the patient, determined 
via genotyping or using in silico methods, as well as the FASTA file generated in the 
previous step comprising mutated and WT 17-21-mer sequences. Typically, antigenic 
epitopes presented by HLA class I molecules can vary in length and are in the range of eight 
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to 11 amino acids (aa). Hence, we recommend specifying the same range when running 
epitope prediction software. 
 
Parse and filter the output 
Starting with the output list of all possible epitopes from the epitope prediction software, we 
apply specific filters to choose the best candidate mutant peptides. First, we restrict further 
consideration to strong- to intermediate-binding peptides by focusing on candidates with a 
mutant (MT) binding score of less than 500 nM. Second, epitope binding calls are evaluated 
only for those peptides that contain the mutant amino acid (localized peptides). This filter 
eliminates any WT peptides that may overlap between the two FASTA sequences. Our 
workflow enables screening across multiple lengths and multiple alleles very efficiently. If 
predictions are run to assess multiple epitope lengths (for example, 9-mer, 10-mer, and so 
on), and/or to evaluate all patient’s HLA-A, -B, and -C alleles, we review all localized 
peptides and choose the single best binding value representative across lengths (9 aa, 10 aa, 
and so on) based on lowest binding score for MT sequence. Furthermore, we choose the ‘best 
candidate’ (lowest MT binding score) per mutation between all independent HLA alleles that 
were used as input. Additionally, in the output file, the WT peptide binding score is provided. 
Although this score may not directly affect candidate choice or immunogenicity, end users 
may find this comparative information useful. 
 
2.3.3 Integrate expression and coverage information 
We subsequently apply several filters to ensure we are predicting neoantigens that are 
expressed as RNA variants, and that have been predicted correctly based on coverage depth 
in the normal and tumor tissue datasets. We have found that gene expression levels from 
RNA-Seq data, measured as fragments per kilobase of exon per million reads mapped 
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(FPKM), provide a good method to filter only the expressed transcripts. We used the tuxedo 
suite - Tophat103,104 and Cufflinks105 - as part of the GMS to align RNA-Seq data and 
subsequently infer gene expression for our in-house sequencing data. Depending on the type 
of RNA prep kit, Ovation® RNA-Seq System V2 (NuGEN Technologies, Inc., San Carlos, 
CA, USA) or TruSeq Stranded Total RNA Sample Prep kit (Illumina, Inc., San Diego, CA, 
USA) used, Tophat was run with the following parameters: Tophat v2.0.8 ‘--bowtie-
version = 2.1.0’ for Ovation, and ‘--library-type fr-firststrand --bowtie-version = 2.1.0’ for 
Truseq. For Ovation data, prior to alignment, paired 2 × 100bp sequence reads were trimmed 
with Flexbar version 2.21106 (params: --adapter CTTTGTGTTTGA --adapter-trim-end LEFT 
--nono-length-dist --threads 4 --adapter-min-overlap 7 --maxuncalled 150 --min-readlength 
25) to remove single primer isothermal amplification adapter sequences. Expression levels 
(FPKM) were calculated with Cufflinks v2.0.2 (params: --max-bundle-length = 10000000 --
num-threads 4). 
 
For selecting unique vaccine candidates, targeting the best ‘quality’ mutations is an important 
factor for prioritizing peptides. Sequencing depth as well as the fraction of reads containing 
the variant allele (VAF) are used as criteria to filter or prioritize mutations. This information 
was added in our pipeline via bam-readcount107. Both tumor (from DNA as well as RNA) and 
normal coverage are calculated along with the VAF from corresponding DNA and RNA-Seq 
alignments. 
 
2.3.4 Filter neoepitope candidates 
Since manufacturing antigenic peptides is one of the most expensive steps in vaccine 
development and efficacy depends on selection of the best neoantigens, we filter the list of 
predicted high binding peptides to the most highly confident set, primarily with expression 
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and coverage based filters. The pVAC-Seq pipeline permits user-specified filters, and we 
encourage new users to experiment with these cutoffs in order to tailor the pipeline to their 
input data and analysis needs. We employ the following filters: (a) Depth based filters: We 
filter out any variants with normal coverage <=5× and normal VAF of >=2%. The normal 
coverage cutoff can be increased up to 20× to eliminate occasional misclassification of 
germline variants as somatic. Similarly, the normal VAF cutoff can be increased based on 
suspected level of contamination by tumor cells in the normal sample. 
 
For tumor coverage from DNA and/or RNA, a cutoff is placed at >=10× with a VAF 
of >=40%. This ensures that neoantigens from the founder clone in the tumor are included, 
but the tumor VAF can be lowered to capture more variants, which are less likely to be 
present in all tumor cells. Alternatively, if the patients are selected based on a pre-existing 
disease-associated mutation such as BRAF V600E in the case of melanoma, the VAF of the 
specific presumed driver mutation can be used as a guide for assessing clonality of other 
mutations. Also, other known driver mutations such as KRAS G12/G13 or NRAS Q61 may 
be used to determine purity, and to subsequently adjust the VAF filters to target founder 
clone mutations. (b) Expression based filters: As a standard, genes with FPKM values greater 
than zero are considered to be expressed. We slightly increase this threshold to 1, to eliminate 
noise. Alternatively, we analyze the FPKM distribution (and the corresponding standard 
deviation) over the entire sample, to determine the sample-specific cutoffs for gene 
expression. Spike-in controls may also be added to the RNA-Seq experiment to assess quality 
of the sequencing library and to normalize gene expression data. Since alternative splicing 
can give rise to multiple transcripts that encompass the variant residue, optionally, all these 
transcripts could be included in analysis during the annotation step. However, one should be 
careful as this could potentially give rise to transcripts that do not include the variant. Also, 
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long transcripts or transcripts with high G/C content might show some bias if RNA-CapSeq is 
used but in our experience are generally well represented. The primary goal of using RNA-
(Cap)Seq data in our method is to address to questions of primary importance: (1) is the gene 
expressed at a reasonably high level (for example, FPKM >1); and (2) is the variant allele 
expressed in the RNA-seq fragment population. 
 
This filtered list of mutations is manually reviewed via visual inspection of aligned reads in a 
genome viewer like IGV108,109  to reduce the retention of obvious false positive mutations. 
 
2.3.5 Dataset 
To demonstrate the workings of our in silico pVAC-Seq pipeline, we applied it to four 
metastatic melanoma patients, the clinical results for three of whom were described 
previously71. In brief, there were three patients (MEL21, MEL38, MEL218) with stage III 
resected cutaneous melanoma, all of whom had received prior treatment with ipilimumab, 
and one patient (MEL69) with stage IV cutaneous melanoma. All four patients were enrolled 
in a phase 1 vaccine clinical trial (NCT00683670, BB-IND 13590) employing autologous, 
functionally mature, interleukin (IL)-12p70-producing dendritic cells (DC). Informed consent 
for genome sequencing and data sharing was obtained for all patients on a protocol approved 
by the Institutional Review Board of Washington University. We performed genomic 
analysis of their surgically excised tumors to select candidates for the personalized DC 
vaccine. Three of these patients (MEL21, MEL38, MEL69) had multiple metachronous 
tumors. Exome sequencing as well as RNA-CapSeq was performed for each of these tumors, 
and their corresponding matched normal tissue. The raw exome and transcriptome sequence 
data are available on the Sequence Read Archive database: Bioproject PRJNA278450, and 
corresponding dbGaP accession: phs001005. 
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2.4 Results and Discussion 
Since melanoma patients harbor hundreds of mutations, it can be challenging to filter down 
and target the best set of potentially immunogenic neoantigens for vaccine design. For each 
of the four metastatic melanoma patients, we used the annotated list of SNVs generated using 
the GMS strategy described above, and analyzed them via our pVAC-Seq pipeline. As 
mentioned earlier, for the demonstration of this workflow, amino acid changes resulting from 
only missense mutations were considered for analysis. Table 2.1 shows the breakdown of 
these SNVs described previously71 and the data generated in subsequent steps through our 
workflow, leading to a high-confidence list of neoepitopes. As part of our local workflow, 
NetMHC v3.4 was used as the epitope prediction software to generate HLA class I restricted 
epitopes. 
 
 MEL21 MEL38 MEL218 MEL69 
 LN 
(2011) 
Skin 
(2012) 
Skin 
(2013) 
Axilla      
(2012) 
Breast 
(2013) 
AbW
all 
(2013) 
LN 
(2005) 
Skin / 
Limb 
(2013) 
Skin / 
Scalp 
(2013) 
Total SNVs 702 838 1099 359 402 385 695 256 282 
Missense 
SNVs 
443 515 598 219 247 238 437 141 162 
21-mer 
FASTA 
entries (WT 
& MT) 
856 1004 1002 424 482 462 850 272 314 
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Raw 
NETMHC 
output (9-
mers) 
11152 
*2 
(HLA-
A02:01, 
HLA-
A01:01) 
13072 
*2 
(HLA-
A02:01, 
HLA-
A01:01) 
13044 
*2 (HLA-
A02:01, 
HLA-
A01:01) 
5512*3       
 (
HLA-
A02:01, 
HLA-
A31:01, 
HLA-
B07:02) 
6270*3       
(HLA-
A02:01, 
HLA-
A31:01, 
HLA-
B07:02) 
6010 
*3      
 
(HLA-
A02:01, 
HLA-
A31:01, 
HLA-
B07:02) 
11050*3      
 (
HLA-
A02:01, 
HLA-
A03:01, 
HLA-B44:02 
3542 *2       
(HLA-
A02:01, 
HLA-
A11:01) 
4088 *2       
 
(HLA-
A02:01, 
HLA-
A11:01) 
Parsed 
NetMHC 
output 
(comparing 
WT with MT) 
3796 *2        
 
(HLA-
A02:01, 
HLA-
A01:01) 
4465 *2    
(HLA-
A02:01, 
HLA-
A01:01) 
4458 * 2  
(HLA-
A02:01, 
HLA-
A01:01) 
1871*3        
(HLA-
A02:01, 
HLA-
A31:01, 
HLA-
B07:02) 
2131*3       
(HLA-
A02:01, 
HLA-
A31:01, 
HLA-
B07:02) 
2042 
*3       
 
(HLA-
A02:01, 
HLA-
A31:01, 
HLA-
B07:02) 
3770 *3        
(HLA-
A02:01, 
HLA-
A03:01,   
HLA-B44:02 
1217 *2       
(HLA-
A02:01, 
HLA-
A11:01) 
1395 *2       
(HLA-
A02:01, 
HLA-
A11:01) 
Filter 1: 
Binding 
based 
110 121 144 103 112 111 161 50 65 
HLA-A02:01 
candidates 
only 
79 96 111 52 48 46 93 25 34 
Filter 2: 
Manually 
reviewed 
HLA-A02:01 
candidates  
(Exome plus 
RNA-Seq) 
11 11 12 14 16 16 24 6 12 
Filter 3: 
Experimental
ly tested 
16 14 18 12 
Filter 4: 
Vaccine 
tested 
7 7 7 7 
Immunogenic
ity 
3 3 3 3 
Table 2.1 Summary of predicted epitope candidates through pVAC-Seq pipeline 
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The table illustrates the number of raw candidates predicted by NetMHC, and the parsing and 
filtering strategies applied thereafter to the final list of neoantigen candidates. These 
candidates were then communicated to our vaccine design collaborators who evaluated this 
list by patient-specific immunological assays (Filters 3 & 4)71  
 
As is evident from Table 2.1, there were multitudes of epitopes reported by NetMHC v3.4 in 
its raw format. This number increased even further with the addition of each HLA class I 
allele. Using pVAC-Seq, and its recommended thresholds for filtering (binding and coverage-
based), we were able to produce a more reasonable list of high affinity HLA class I binding 
neoantigen candidates for experimental validation. 
 
These candidate neoantigens were experimentally tested in binding assays and those with 
confirmed binding to HLA class I restricting molecules were incorporated in the vaccine 
formulation71. Since all of these patients harbor the BRAF V600E mutation, we used its VAF 
in each sample as a comparative control of tumor purity and clonality. Integration of variant 
coverage information from Exome and RNA-Seq (VAF), as well as mutant expression 
information (FPKM), provided additional information needed to make an informed decision 
on the number and identity of peptides to include in each patient-specific vaccine (Figure 
2.3, Figure 2.4, Figure 2.5, and Figure 2.6). 
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Figure 2.3 Landscape of filtered neoantigen candidates in MEL21. This figure illustrates 
the landscape of neoantigen vaccine candidates in patient MEL21 after being prioritized 
using the pVAC-Seq pipeline. The points represent the overall sequencing information: 
exome and RNA VAFs, gene expression in terms of log2 FPKM value, as well log2 fold 
change, calculated as the ratio of WT binding affinity over mutant binding affinity. 
Recommended exome and RNA VAF cutoffs are also indicated. Candidates that were 
incorporated in the vaccine are labeled based on the genes containing these somatic 
mutations. Red boxes depict naturally occurring (that is, pre-existing T cell response) and 
blue boxes denote vaccine-induced neoantigens that were recognized by T cells. Since BRAF 
was used as a guide for assessing clonality of other mutations, it is also shown in each of 
three metachronous tumors (from the same patient) 
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Figure 2.4 Landscape of filtered neoantigen candidates in MEL38 This figure illustrates 
the landscape of neoantigen vaccine candidates in patient MEL38 after being prioritized 
using the pVAC-Seq pipeline. The points represent the overall sequencing information: 
exome and RNA VAFs, gene expression in terms of log2 FPKM value, as well log2 fold 
change, calculated as the ratio of WT binding affinity over mutant binding affinity. 
Recommended exome and RNA VAF cutoffs are also indicated. Candidates that were 
incorporated in the vaccine are labeled based on the genes containing these somatic 
mutations. Red boxes depict naturally occurring (that is, pre-existing T cell response) and 
blue boxes denote vaccine-induced neoantigens that were recognized by T cells. Since BRAF 
was used as a guide for assessing clonality of other mutations, it is also shown in each of 
three metachronous tumors (from the same patient).  
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Figure 2.5 Landscape of filtered neoantigen candidates in MEL218 This figure illustrates 
the landscape of neoantigen vaccine candidates in patient MEL218 after being prioritized 
using the pVAC-Seq pipeline. The points represent the overall sequencing information: 
exome and RNA VAFs, gene expression in terms of log2 FPKM value, as well log2 fold 
change, calculated as the ratio of WT binding affinity over mutant binding affinity. 
Recommended exome and RNA VAF cutoffs are also indicated. Candidates that were 
incorporated in the vaccine are labeled based on the genes containing these somatic 
mutations. Red boxes depict naturally occurring (that is, pre-existing T cell response) and 
blue boxes denote vaccine-induced neoantigens that were recognized by T cells. Since BRAF 
was used as a guide for assessing clonality of other mutations, it is also shown.  
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Figure 2.6 Landscape of filtered neoantigen candidates in MEL69. This figure illustrates 
the landscape of neoantigen vaccine candidates in patient MEL69 after being prioritized 
using the pVAC-Seq pipeline. The points represent the overall sequencing information: 
exome and RNA VAF cutoffs, gene expression in terms of log2 FPKM value, as well log2 fold 
change, calculated as the ratio of WT binding affinity over mutant binding affinity. 
Recommended exome and RNA VAFs are also indicated. Candidates that were incorporated 
in the vaccine are labeled based on the genes containing these somatic mutations. Red boxes 
depict naturally occurring (that is, pre-existing T cell response) and blue boxes denote 
vaccine-induced neoantigens that were recognized by T cells. Since BRAF was used as a 
guide for assessing clonality of other mutations, it is also shown in both the metachronous 
tumors 
 
 
As shown, if existing epitope prediction software tools were solely used to generate 
neoantigen predictions in these patients, it would have been challenging to integrate the filters 
as well as the important digital sequencing metrics that ultimately determined the ‘quality’ of 
these candidates. By implementing the novel methods reported in this manuscript, we were 
able to rapidly streamline the screening and identification of a smaller number of potentially 
immunogenic neoepitopes within the landscape of all neoepitopes. This method can be 
further extended to include other genomic alterations such as frame-shift insertions and 
deletions, splicing aberrations, and gene fusions, which may in some cases cause larger 
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changes in epitope binding affinities. We are currently testing approaches to include binding 
predictions from frame-shift insertions and deletions by incorporating VEP annotation, and 
once tested, will be adding this functionality to the github repository for pVAC-Seq. By 
expanding the focus from just somatic point mutations to the entire neoantigen landscape, it 
may also be possible to better assess whether neoantigen load itself can serve as a biomarker 
for prediction of checkpoint blockade response. 
 
2.5 Conclusions 
The current regimen for predicting and screening neoantigens from sequencing data is 
laborious and involves a large number of intermediate steps such as creating FASTA files, 
running the prediction algorithms (most of the time online), and filtering output for high 
binding affinity candidates. Our flexible, automated in silico workflow, pVAC-Seq, provides 
higher efficiency and faster turnaround by automating many of these steps. This approach 
should help to evaluate tumor-specific neoepitopes in a much-reduced time, thereby 
increasing its applicability for clinical use. As we learn from ongoing early mouse and human 
trials, the methods developed will help optimize the composition of personalized cancer 
vaccines with high precision and will expedite vaccine design to address growing clinical 
demand. 
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Chapter 3: Accounting for proximal 
variants improves neoantigen prediction 
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3.1 Introduction 
Over the past two decades, approaches to identify and screen for antigens, both self and non-
self, have evolved rapidly32,110. This is due in part to advances in sequencing technologies, in 
the accuracy of algorithmic identification of somatic variants, and in computational modeling 
to predict the binding affinity of the resulting novel, tumor-specific peptides to major 
histocompatibility complex (MHC) molecules45. Thus, current immunogenomic approaches 
can identify somatic variants that give rise to tumor-specific mutant antigens or ‘neo’-
antigens and evaluate their ability to bind to MHC Class I and Class II molecules45. 
 
Typically, to evaluate strong-binding neoantigens from genomic sequencing data, the raw 
sequencing reads from tumor and normal DNA libraries are aligned to the human reference 
genome, and somatic variants are identified by comparison of tumor to normal read 
alignments. The resulting somatic variants of interest (SVOI) are then annotated to predict 
protein sequence changes and to infer possible neoantigenic peptides. Individual neoantigenic 
peptides are selected by sliding an amino acid window (usually 8-11-mers) across the variant 
position to consider each possible ‘register’. These peptides are assessed using various 
algorithms to predict binding affinity to MHC and determine the strongest binding epitopes. 
These predicted neoantigenic peptides are prioritized as we have previously described111. The 
cancer vaccine design process, from read alignment to variant calling and neoantigen 
prediction typically assumes the reference genome sequence surrounding each somatic 
variant is representative of the patient’s genome sequence.  
 
However, any sequence variant proximal to an SVOI in the patient’s genome that differs 
from the human reference may alter the amino acid sequence of the resulting peptide (note, 
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proximal is defined here as ‘situated close to’ or ‘nearby’, not the classic genetics meaning of 
‘closer to the centromere’). Existing pipelines that are used for computational prediction of 
neoantigens from sequencing data, such as MuPeXI112 and pVAC-Seq111, do not explicitly 
incorporate patient-specific nearby germline or somatic variants (collectively referred to as 
‘proximal variants’ hereafter) into the peptide sequence considered in neoantigen prediction. 
Some pipelines such as Vaxrank113 infer the coding sequence from assembly of tumor RNA 
reads, thus accounting for both somatic and germline variants implicitly, but this is largely 
dependent on the availability of RNA-Seq data. Failing to account for patient-specific nearby 
germline or somatic variants (i.e. proximal variants) could impact the efficacy of a vaccine, 
possibly resulting in immunization with incorrect peptides or failure to identify highly 
neoantigenic peptides. 
 
To investigate these possibilities, we identified somatic and germline variants proximal to 
SVOIs in a data set of tumor sequencing studies representing different tissue sites and 
mutational loads.  For this analysis, given that the upper-bound for the length of MHC-
binding peptides (accounting for both Class I and Class II) is typically considered to be 30 
amino acids114,115  we chose a nucleotide window of 89 bp upstream and downstream of each 
SVOI in which to identify relevant proximal variants (Methods). We limited our analysis to 
only include missense proximal variants and SVOIs. We then incorporated these proximal 
variants in the final peptide sequences (proximal variant correction; PVC) and re-evaluated 
the resulting peptide set using our neoantigen prediction pipeline (pVAC-Seq)111. Our results 
suggest that taking individual proximal variation into account can have a significant effect on 
the accuracy of neoantigen selection, resulting in a more personalized vaccine design.  
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Figure 3.1: Overview of the pipeline for proximal variant correction The steps required for 
incorporating and assessing the impact of proximal variants on neoantigen binding 
prediction are depicted as a flow diagram. There are three main steps. (A) Alignment and 
variant calling of matched tumor (pink) and normal (green) sequencing data. (B) Phasing of 
proximal somatic and germline variants: The pink bars represent the tumor sequence reads, 
with mismatches/sequencing errors shown in small gray rectangles. For a somatic variant of 
interest (SVOI; labeled with a red flag), we scan 89 bp on either side to assess for proximal 
germline or somatic SNVs (labeled with blue and orange boxes). These proximal variants are 
then phased together to determine linkage. Only proximal variants that are in phase (orange 
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box) with the SVOI (red box) are considered for downstream neoantigen analysis. Other (out-
of-phase) proximal variants (blue box) are ignored. (C) Neoantigen binding predictions are 
then assessed after performing proximal variant correction (PVC). The left panel shows the 
‘uncorrected’ wildtype and mutant peptides along with their respective binding scores for a 
single SVOI example. The right panel shows PVC (‘corrected’) peptides and scores for this 
SVOI. 
 
 
3.2 Methods 
3.2.1 Sequence data alignment and variant calling 
To investigate the prevalence of proximal variants (germline SNPs or somatic variants), we 
analyzed publicly available sequencing data from the TCGA as well as datasets generated in-
house, altogether representing seven different tissue sites. These data sets were chosen to 
adequately represent low, medium and high mutational burden tumors.  
 
Analysis of in-house whole genome/exome sequencing datasets was performed as previously 
described111,86,116. Briefly, raw sequencing reads from both the tumor and normal were 
aligned to the human reference genome sequence (either GRCh37 or GRCh38) using 
BWA117, then merged and deduplicated using Picard (see URLs). A combination of three or 
four different variant callers was used to identify somatic variants by comparison of tumor 
and normal variant calls: Samtools93, Sniper95, Strelka98, and VarScan96,97. These variants 
were filtered as previously described118,119 and then manually reviewed using IGV per the 
standard operating procedures120 to obtain a list of high confidence variant calls.  On average, 
80% of the filtered variants passed manual review. Germline variant analysis of the normal 
samples was performed using Samtools. 
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For the TCGA data, aligned tumor and normal BAMs from BWA (version 0.7.12-r1039) as 
well as somatic variant calls from VarScan2 (in VCF format) were downloaded from the 
Genomic Data Commons (GDC). We restricted our analysis to only consider ‘PASS’ variants 
in these VCFs that are higher confidence than the raw set. Since TCGA does not provide 
germline variants, we used GATK’s HaplotypeCaller to perform germline variant calling 
using default parameters. These calls were refined using VariantRecalibrator in accordance 
with GATK Best Practices121. 
 
For this study, we restricted the variant calls to only include missense SNVs, in both- TCGA 
as well as in-house datasets. 
 
3.2.2 Phasing of variants to assess linkage 
Somatic and germline missense variant calls from each sample were combined using 
GATK’s CombineVariants, and the variants were subsequently phased using GATK’s 
ReadBackedPhasing algorithm.  
In silico HLA-typing  
OptiType48 was used to perform in silico HLA typing for the in-house samples. For the 
datasets downloaded from TCGA, existing in silico HLA typing information was obtained 
from The Cancer Immunome Atlas (TCIA122) database. 
 
3.2.3 Choosing an appropriate window for neoantigen analysis 
Due to the absence of patient-specific HLA Class II typing information, we limited our 
neoantigen binding prediction analysis to MHC Class I, though we believe that the Class II 
peptides are also important in contributing to immunogenicity. Hence, our nucleotide window 
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was chosen such that it encompasses both Class I and Class II MHC peptide lengths, to 
demonstrate the prevalence of proximal variants within that genomic region. Most strong-
binding Class I MHC peptides are around 8-11 amino acids in length. There is no length 
restriction on Class II MHC peptides due to an open binding groove, and longer peptide 
lengths are much more common, typically 13-25-mers123 but peptides as long as 30-mer have 
been reported114,115. The majority (99.2%) of human linear T-cell epitopes with MHC class II 
restriction currently reported in IEDB 82are 8-30-mers. To  identify the best binding 30-mer 
around a missense variant of interest, one would ideally scan 29 amino acids upstream and 
downstream of the mutant (MT) amino acid, hence a window of 59 amino acids. At the 
nucleotide level, this corresponds to 87 nucleotides. Given that the frame of the missense 
mutation is not always known, we allow for 2 extra bases leading to a window size of 89 
nucleotides on each side of the SVOI. 
 
The appropriate nucleotide window for any peptide length can be calculated using this 
formula: ((peptide length -1)*3)+2. 
 
3.2.4 Corrected neoantigen binding prediction using pVACtools 
For each sample, the phased variant calls as well as the somatic variant calls were annotated 
using Variant Effect Predictor (VEP4), specifically using the Downstream plugin as well as 
the custom Wildtype plugin, available via pVACtools (see URLs) . To evaluate the effect of 
relevant nearby variants on neoantigen identification, we re-assessed the binding affinities of 
the neoantigens with the corrected mutant peptide sequence (Figure 3.1C), using 
NetMHCv4.056,57 via an updated version of the pVACtools software. This version takes as 
input the VEP-annotated phased VCF file of somatic and germline variants, in addition to the 
existing VEP-annotated somatic VCF.  
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3.2.5 Calculating False Discovery and False Negative Rates 
To calculate FNR and FDR, we first determined the number of weak binders before PVC that 
were falsely omitted (false negatives (FN)), as well as the number of peptides that were 
identified as strong binders before PVC, but whose sequence (MTpeptide) was altered due to 
a proximal variant and which were thus incorrectly considered during neoantigen selection 
(false positives (FP)). We also calculated the number of peptides that were identified strong 
binders before correction and remained unaltered by proximal variants (true positives (TP)). 
 𝐹𝑁 ∶  𝑀𝑇𝑠𝑐𝑜𝑟𝑒!"#$%%&#'&( >  500 𝑛𝑀  Λ 𝑀𝑇𝑠𝑐𝑜𝑟𝑒!"##$!%$& < 500 𝑛𝑀  𝐹𝑃 ∶  𝑀𝑇𝑠𝑐𝑜𝑟𝑒!"#$%%&#'&( <  500 𝑛𝑀  Λ  (𝑀𝑇𝑝𝑒𝑝𝑡𝑖𝑑𝑒_𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑  ≠  𝑀𝑇𝑝𝑒𝑝𝑡𝑖𝑑𝑒_𝑢𝑛𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑) 𝑇𝑃 ∶   (𝑀𝑇𝑠𝑐𝑜𝑟𝑒!"#$%%&#'&( < 500𝑛𝑀)  Λ  (𝑀𝑇𝑝𝑒𝑝𝑡𝑖𝑑𝑒_𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 ≡   𝑀𝑇𝑝𝑒𝑝𝑡𝑖𝑑𝑒_𝑢𝑛𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑) 
 𝐹𝑁𝑅 = 𝐹𝑁𝐹𝑁 + 𝑇𝑃 
 𝐹𝐷𝑅 = 𝐹𝑃𝐹𝑃 + 𝑇𝑃 
 
The FNR is then defined as the number of false negatives divided by the number of false 
negatives plus the number of true positives. The FDR is defined as the number of false 
positives divided by the number of all positive calls, including both true positives and false 
positives. 
 
3.3 Results 
To determine how frequently proximal variants occur within the vicinity of an SVOI, we 
assessed 430 tumors with varying mutational loads identified from whole genome/exome 
sequence data of matched normal and tumor tissue (Figure 3.1, Methods). Specifically, data 
from 100 cases each of melanoma, hepatocellular carcinoma and lung squamous cell 
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carcinoma were obtained from TCGA. We also evaluated data from 48 cases of HER2+ 
breast cancer, 34 cases of small cell lung cancer, 30 cases of hepatocellular carcinoma, 15 
cases of oral squamous cell carcinoma, and one hypermutated glioblastoma (one primary and 
two metastatic samples) from in-house studies. After performing alignment and variant 
calling, we confirmed the linkage of SVOIs and proximal (somatic or germline) variants by 
phasing the variants using GATK124 [Figure 3.1B] (Methods). Then, the list of SVOIs from 
each of the samples was intersected with the respective lists of in-phase amino acid-altering 
proximal variants to assess their presence within the chosen nucleotide window. 
  
3.3.1 Missense variants overlap with missense proximal variants 
Out of 430 tumor samples analyzed, 380 samples (88.3%) had at least one (range: 1 to 377) 
missense SVOI in phase with a proximal missense variant. Of a total of 103,673 missense 
variants identified in these tumors, there were 7,783 SVOIs (7.5%) with a proximal missense 
variant (somatic or germline) within 89 nucleotides on either side. 5,344 of these missense 
SVOIs (5.1%) were also in phase with their respective proximal variants. In most cases 
(93.8%), SVOIs had a single proximal germline or somatic variant in phase, but occasionally 
multiple (range: two to six) variants were proximal to the SVOI. An average of 241 missense 
somatic variants were analyzed per sample. Per patient, an average of 6.5% of SVOIs had a 
proximal missense variant, and 5% had one or more proximal missense variants in phase with 
the SVOI. On average, 62.2% of these proximal variants were germline missense variants and 
37.7% were somatic missense variants. The majority (68.0%) of proximal somatic variants 
were contributed by Dinucleotide Polymorphisms (DNPs). Most variant callers (including 
those used for the harmonized analysis of TCGA data in the Genomic Data Commons) report 
DNPs as two separate SNVs. Excluding the DNPs, on average, 88.4% of the proximal 
variants were germline missense SNPs, and 11.6% were somatic missense SNVs.  
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3.3.2 Predicted binding affinity changes with PVC 
To identify neoantigens capable of eliciting an effective anti-tumor T-cell response, it is 
critical to both determine the correct tumor specific peptide sequence and assess its ability to 
bind MHC125. First, we sought to assess how accounting for proximal variants in the 
neoantigen peptide sequence may influence binding affinity to MHC. In order to evaluate 
this, we quantified the impact of missing or incorrectly selecting strong-binding neoantigens 
when ignoring proximal variants. We compared binding affinity scores before and after PVC 
for each patient’s peptides against their respective MHC Class I alleles.  
 
A typical Class I neoantigen binding evaluation and screening is carried out by sliding over 
shorter sub-peptide registers111. To evaluate strong-binding Class I neoantigens of lengths 8-
11-mers, we ideally scan 7-10 amino acids on each side of the mutated amino acid resulting 
from the SVOI. Even if a proximal variant alters an amino acid in the full peptide window, it 
may not be included in every register we consider as a candidate neoantigen (Figure 3.2). 
 
 
Figure 3.2 Example of candidate neoantigen evaluation This figure shows the possible sub-
peptide registers for selection of a candidate neoantigen of length 9. The 17-mer peptide 
window for a 9-mer candidate is selected by scanning 8 amino acids on each side of the 
mutated amino acid resulting from the SVOI (red box). Only those registers that contain 
amino acid changes resulting from both - the proximal variant (PV; orange box), as well as 
the SVOI (red box) were considered for this analysis (five peptides shown in yellow for this 
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example). The remaining registers shown (grey boxes) contain the SVOI but are not affected 
by the proximal variant. 
 
 
In some rare cases, a proximal variant may translate to the same amino acid sequence as the 
SVOI, or the SVOI and proximal variant both lead to amino acid changes if considered in 
isolation, but if they are in phase and considered together, they result in no change to the 
amino acid sequence. To take into account these cases and accurately assess the effect of 
amino-acid changes due to proximal variants on binding predictions, we only considered 
those registers that contained both the proximal variant and the SVOI amino acid changes, 
when translated together. Across 8-11-mers, on average 45.95% of all neoantigen peptide 
registers contained both. Figure 3.3 summarizes the effect of proximal variants on 
neoantigen binding affinity. Although the effect is less pronounced for 8-mers, the smallest 
length we examined, we see drastic changes in binding affinity due to PVC across all four 
peptide lengths (represented as log10 of mutant (MT) epitope fold change 
(MTuncorrected/MTcorrected), with ranges spanning from -3.0 to 3.1 for 8-11-mers (Figure 3.3A). 
Figures 3.3C-D show the distribution of log(MT fold change) scores for 9-mer and 10-mer 
peptides, respectively. For both peptide lengths, most weak binders stay within the same 
range before and after PVC but very few strong binders remain unchanged, after PVC. We 
chose 500 nM as the binding affinity cutoff for a potential binder, as most known T-cell 
epitopes have an affinity value of less than 500 nM126. For the binding prediction changes, we 
only considered a call as erroneous if PVC yielded at least a 10% change in predicted binding 
affinity.  
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Figure 3.3 Mischaracterization of neoantigens before proximal variant correction  
The effect of accounting for proximal variants in neoantigen selection is summarized in 
several ways (n=380 biologically independent samples with at least one proximal variant). 
(A) Violin plot (distribution of all data in blue and whiskers indicating max/min values) 
showing the change in uncorrected neoantigen binding using the existing approach 
(MTuncorrected) versus PVC (MTcorrected), represented as log10 MT fold change (MTuncorrected / 
MTcorrected) across 8-11-mers for all variants in phase with the somatic variant of interest. (B) 
For 8-11-mer peptides, the False Negative Rate (FNR) (shown as orange bars) represents the 
number of instances when a truly strong-binding peptide was mistaken as a weak-binding 
peptide (MTuncorrected > 500 nM, and MT fold-change < 1.1 ). The False Discovery Rate 
(FDR) (shown in blue bars) represents the number of instances where a strong-binder before 
PVC (MTuncorrected < 500nM) is determined to have an incorrect peptide sequence as a result 
of a proximal variant. (C) Log10 scaled comparison of corrected versus uncorrected binding 
scores for 9-mer peptides considering patient-specific MHC Class I alleles. Dotted lines 
demarcate the binding affinity threshold of 500 nM. (D) Log10 scaled comparison of 
corrected versus uncorrected binding scores for 10-mer peptides considering patient-specific 
MHC Class I alleles. 
 
 
 67 
 
3.3.3 Impact of PVC on False Discovery and False Negative Rates 
In addition to the effect a proximal amino acid substitution may have on a neoantigen’s 
binding potential, it is also important to consider whether the peptide sequence of the selected 
neoantigen is correct and representative of the sequence in the tumor. Failure to do so may 
affect the immunogenic potential of the neoantigen being selected, as the uncorrected 
neoantigen will not produce tumor-specific T-cells, even if it binds well and is presented by 
the MHC. 
 
To determine how many neoantigens were being erroneously predicted, and the effect that 
mischaracterization of neoantigens due to proximal variants would have on candidate 
selection, we calculated the False Negative Rate (FNR) and False Discovery Rate (FDR) after 
applying PVC. The FNR and FDR represent probabilities of potential MHC binders (binding 
affinity < 500 nM) being discarded (false negatives) and of erroneous peptides being 
mistaken for potential binders (false positives), respectively.  
 
An average of 9 SVOI and 10 neoantigenic peptides were mischaracterized per case. As a 
consequence, 1,165 potential binders (MTcorrected < 500 nM) were erroneously rejected, and 
3,305 peptides which were strong binders before PVC were misidentified across all 430 
patients investigated here. Overall, FNR and FDR across lengths 8-11 were 0.026 and 0.069, 
respectively (Figure 3.3B). 
 
As a representative example, Figure 3.4 illustrates data from one of the TCGA melanoma 
samples with a heterozygous missense SNV in the reverse strand gene MARCH10 that 
overlaps an in-phase heterozygous germline single nucleotide polymorphism (SNP), 21 
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nucleotides upstream. When translated, this germline SNP results in S357F 
(NP_001275708.1:p.Phe357Ser) alteration that is 7 amino acids downstream to the missense 
somatic variant F350S (NP_001275708.1:p.Ser350Phe). This variant directly affects the final 
neoantigen sequence for a peptide of any length (> 8-mer). To evaluate the effect of this 
germline SNP on the binding affinity of the neoantigen peptide, we calculated the binding 
affinity of the uncorrected versus the PVC neoantigenic peptides. The binding affinity of the 
best register for a 10-mer peptide using the uncorrected approach (MTuncorrected = 55.44 nM) is 
within the range for a good binder (< 500 nM). However, after including this patient’s 
proximal germline variant, the binding affinity for the same register decreases almost 70-fold 
(MTcorrected = 3766.72 nM), thus predicting a very weak binder. Using the uncorrected 
analysis approach, one might have selected this neoantigenic peptide for a vaccine but after 
PVC, the candidate peptide is unsuitable. This result illustrates the importance of using the 
individual variation of the germline genome while selecting and designing neoantigens for 
personalized immunotherapy. 
 
Figure 3.4 Example of a germline SNP within the proximity of a somatic SNV An example 
from one of the TCGA melanoma samples with a missense SNV that overlaps a germline SNP 
(dbSNP ID: rs9891498), 21 nucleotides upstream. When translated, the germline SNP results 
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in S357F (NP_001275708.1:p.Phe357Ser) alteration and is 7 amino acids downstream of the 
missense somatic variant F350S (NP_001275708.1:p.Ser350Phe)  in MARCH10. 
 
 
3.4 Discussion 
There are some caveats/limitations of our approach. Firstly, the analysis was restricted only 
to single nucleotide changes (i.e. missense somatic SNVs that are near another germline or 
somatic SNV), and did not seek to evaluate whether other, potentially relevant types of 
variants were found nearby. These include insertions and deletions (both somatic and 
germline)127 and different types of structural variants that often have a more significant 
impact on peptide sequences but also are rarer than SNVs. Phasing of indels and structural 
variants is also not currently handled by software such as GATK’s ReadBackedPhasing. 
Secondly, our analysis ‘window’ (89 bp) was defined in genomic coordinates. It is 
substantially more complicated to consider this window size in the context of transcriptome 
coordinates, since intronic coordinates must be ignored when scanning upstream and 
downstream. This is further complicated in genes with alternative transcripts and hence 
multiple introns and exons to consider. Our ability to determine phase for variants separated 
by an intron would be limited in WGS or exome data (although could be evaluated in RNA-
seq data with sufficient read lengths). Lastly, for this study, we only considered neoantigen 
binding predictions to MHC Class I molecules. MHC Class II peptides are much longer due 
to an open binding groove and hence, the subsequent impact of proximal variants on the 
peptide sequence would be even more pronounced. Due to these limitations, our results are 
likely an underestimation of the impact of PVC. 
 
Moreover, even with seemingly small false discovery and false negative rates, the importance 
of accounting for the effect of proximal variants is clear when we consider clinical vaccine 
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design scenarios. For example, 10 or fewer peptides are usually selected for the final vaccine 
from a larger number of initial candidates. Given this scenario, we calculated the probability 
of choosing at least 1 weak binder or of omitting 1 strong binder in the final vaccine, without 
PVC. For the first probability, we calculated 1 - (1-FDR)10 = 0.513 and for the second, we 
calculated 1 - (1-FNR)10 = 0.228. The probability that at least one of these errors occurs for 
each patient evaluated, is 1 - (1-FDR)10*(1-FNR)10 = 0.624. Thus, for neoantigen 
identification in 100 patients, we can expect that approximately 51 patients would receive a 
suboptimal vaccine specifically due to receiving a neoantigen with an incorrect peptide 
sequence, 23 would receive a suboptimal vaccine specifically due to missing a strong-binding 
neoantigen, and 62 would receive a suboptimal vaccine due to at least one of these causes. 
 
Design of personalized cancer vaccines is complex, time consuming, and expensive. Previous 
work has shown that only about 16-43% of the predicted neoantigenic peptides included in a 
vaccine formulation yield CD8+ T-cell response69–72. Our study demonstrates the importance 
of ensuring the selected neoantigens correctly represent the individual’s genome and 
therefore maximize the likelihood of eliciting an immune response. PVC based on the 
patient’s genome can eliminate errors during neoantigen candidate selection, potentially 
increasing the efficacy of personalized vaccines. Further studies may also demonstrate the 
importance of considering proximal variants when using neoantigen load to predict response 
to checkpoint blockade inhibition therapies. 
 
3.5 Code availability 
The proximal variant analysis code has now been added to the proximal_variants branch of 
the pVACtools GitHub repository (see URLs). We have also packaged this branch and 
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uploaded the package as an alpha release to TestPyPi. The alpha release can be installed by 
running `pip install -f https://test.pypi.org/project/pvactools/1.0.8/ pvactools==1.0.8` on the 
command line. The feature will be released with the main pVACtools package as part of the 
next software release cycle (version 1.1.0).  
3.5.1 URLs 
Picard: https://broadinstitute.github.io/picard/ 
pVACtools: http://pvactools.org/ 
Github repository for proximal variant analysis code: 
https://github.com/griffithlab/pVACtools/tree/proximal_variants 
 
3.6 Data availability 
Several of the in-house sequencing datasets used in the study have been previously published 
and deposited in various databases. All sequence data for the HER2+ breast cancer samples 
can be accessed via the Database of Genotypes and Phenotypes (dbGAP; study accession: 
phs001291)128. Data for oral squamous cell carcinoma project and hepatocellular carcinoma 
samples are part of other manuscripts currently in preparation, and can be accessed under 
dbGAP study accession phs001623 and phs001106, respectively. Results for the glioblastoma 
case129 and small cell lung cancer119 have been published and can be accessed under dbGAP 
study accessions phs001663 and phs001049, respectively. TCGA data can be accessed under 
dbGaP study accession phs000178. 
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4.1 Introduction 
Increasing interest in identifying the numbers and types of predicted neoantigens encoded by 
a cancer genome has placed an emphasis on the facility and precision of related 
computational prediction tools45.  Several such efforts have been published112,113,130. 
Typically, these tools start with a list of somatic variants (in VCF or other formats), with 
annotated protein changes, and predict the strongest MHC binding peptides (8-11-mer for 
class I MHC and 13-25-mer for class II) using one or more prediction algorithms56,57,131. The 
predicted neoantigens are then filtered or ranked based on quality metrics including 
sequencing read coverage, variant allele fraction, gene expression, and differential binding 
compared to the wild type peptide (agretopicity index score 85). However, of the small 
number of such prediction tools (Table 4.1), most lack some key functionality, including 
predicting neoantigens from gene fusions, aiding optimized vaccine design for DNA cassette 
vaccines, and including nearby germline or somatic alterations into the candidate 
neoantigens132. An intuitive graphical user interface to visualize and efficiently select the 
most promising candidates is also critical to facilitate involvement of clinicians and other 
researchers in the process of neoantigen evaluation.  
 
To address these limitations and to add facility for all end-users, we created a comprehensive 
and extensible framework for computational identification, selection, prioritization and 
visualization of neoantigens - ‘pVACtools’, that facilitates each of the major components of 
neoantigen identification. This computational framework can be used to identify neoantigens 
from a variety of somatic alterations, including gene fusions and insertion/deletion frameshift 
mutations, both of which potentially create very immunogenic neoantigens133. Further, 
pVACtools can facilitate both MHC class I and II predictions, and provides an interactive 
display of predicted neoantigens for review by the end user. 
 
 
 76 
 
   pVACtools Vaxrank113 MuPeXI1
12 
CloudNeo13
0 
FRED2134 Epi-Seq85 ProTect 
(https://gi
thub.com/
BD2KGe
nomics/pr
otect) 
Variant 
calling (within 
the pipeline) 
N N N N N Y Y 
Variant types 
supported 
SNVs, Inframe 
Indels, 
Frameshifts, 
Gene fusions 
(pVACfuse) 
SNVs, Indels,  SNVs, 
Inframe 
Indels, 
Frameshif
ts 
SNVs SNVs, Inframe 
Indels, 
Frameshifts,  
SNVs SNVs 
HLA typing 
(within the 
pipeline) 
N N N Y ( 
PolySolver, 
HLAMiner) 
Y (via separate 
installation of 
OptiType, 
Polysolver, 
Seq2HLA, & 
ATHLATES) 
N Y (Phlat) 
RNA-Seq 
expression 
data filter 
Y (pVACseq) Y Y N N Y Y 
Sequence 
coverage & 
VAF filter 
Y (pVACseq) Y Y (only 
compatibl
e with 
MuTect2 
variant 
calls) 
N N Y N 
Algorithms 
used for 
epitope 
binding 
affinity  
prediction 
IEDB (web and 
local) 
 
(MHC Class I: 
NetMHCpan, 
NetMHC, 
NetMHCcons, 
PickPocket,, 
SMM, 
SMMPMBEC)  
 
MHCflurry 
MHCnuggets 
 
(MHC Class II: 
NetMHCIIpan, 
SMMalign, 
NNalign 
MHCnuggets) 
IEDB (web and 
local) 
 
MHCflurry, 
NetMHC, 
NetMHCpan, 
NetMHCIIpan, 
NetMHCcons,  
 
netMHCp
an (local 
only) 
netMHC, 
netMHCpan 
(local only) 
Local: NetMHC, 
NetMHCPan, 
NetMHCII, 
NetMHCIIpan, 
NetCTLpan, 
PickPocket 
 
Included: 
Select from, 
SMMPMBEC, 
syfpeithi, SMM, 
Tepitopepan, 
ARB,epidemix,  
comblibsidney, 
Unitope, 
HAMMER, 
SVMHC, 
BIMAS, 
NetMHC 
(local 
only) 
IEDB 
(local 
only) 
Stability 
prediction 
Y 
(NetMHCstabpa
n) 
N N N Y 
(NetMHCstabpa
n) 
N N 
Cleavage site 
prediction 
Y (NetChop) Y (NetChop) N N Y (ProteaSMM, 
PCM, Ginodi, 
NetChop) 
N N 
Support for 
vector 
design/epitope 
assembly 
Y (pVACvector) N N N Y (OptiVac) N N 
Incorporation Y Y (RNA only) N N N Y N 
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of proximal 
variants 
(RefHap) 
Unique 
epitope 
ranking 
method 
Y Y (“Total Binding 
Score”) 
Y 
(“Priority 
Score”) 
N Y (OptiTope 
immunogenicity 
score) 
N Y 
(Rankboo
st score) 
Graphical 
User Interface 
Y (pVACviz) N Y 
(http://ww
w.cbs.dtu.
dk/service
s/MuPeXI
/) 
Y (via  NCI 
Cancer 
Genomics 
Cloud 
version) 
Y (EpiToolKit 
2.0) 
N N 
Results 
visualization  
Y (pVACviz) N N N N  N N 
HTTP REST 
API 
Y (pVACapi) N N N Y N N 
License NPOSL-3.0 Apache 2.0 Unknown Apache 2.0 3-clause BSD Unknown Apache 
2.0 
Table 4.1: Comparison of existing software and tools for cancer immunotherapy analysis 
 
4.2 pVACtools workflow 
The pVACtools workflow (Figure 4.1) is divided into flexible components that can be run 
independently. The main tools in the workflow are: (a) pVACseq: a significantly enhanced 
and reengineered version of our previous pipeline111 for identifying and prioritizing 
neoantigens from a variety of tumor-specific alterations (b) pVACfuse: a tool for detecting 
neoantigens resulting from gene fusions (c) pVACviz: a graphical user interface web client 
for process management, visualization and selection of results from pVACseq (d) 
pVACvector: a tool for optimizing design of neoantigens and nucleotide spacers in a DNA 
vector that prevents high-affinity junctional epitopes, and (e) pVACapi: an OpenAPI HTTP 
REST interface to the pVACtools suite. 
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Figure 4.1: Overview of pVACtools workflow: The pVACtools workflow is highly 
modularized and is divided into flexible components that can be run independently. The main 
tools under the workflow include pVACseq111 for identifying and prioritizing neoantigens 
from a variety of somatic alterations (red inset box), pVACfuse (green) for detecting 
neoantigens resulting from gene fusions, pVACviz (blue) for process management, 
visualization and selection of results and pVACvector (orange) for optimizing design of 
neoantigens and nucleotide spacers in a DNA vector. All of these tools interact via the 
pVACapi (purple), an OpenAPI HTTP REST interface to the pVACtools suite. 
 
pVACseq111 has been completely implemented in Python3 and extended to include many new 
features since our initial report of its use. pVACseq no longer requires a custom input format 
for variants, and now uses a standard VCF file annotated with VEP4. In our own neoantigen 
identification pipeline, this VCF is the result of merging results from multiple somatic variant 
callers and RNA expression tools. Information that is not natively available in the VCF 
output from somatic variant callers (such as coverage and variant allele fractions for RNA 
and DNA, as well as gene and transcript expression values) now can be added to the VCF 
using vcf-annotation-tools (vatools.org), a suite of accessory scripts that we created to 
accompany pVACtools. pVACtools queries these features directly from the VCF, enabling 
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prioritization and filtering of neoantigen candidates based on sequence coverage and 
expression information. In addition, pVACtools now makes use of phasing information 
provided in the VCF, taking into account all variants proximal to somatic variants of interest 
that alter neoantigen peptide sequences. Since proximal variants can change the neoantigenic 
peptide sequence and also affect neoantigen binding predictions, this is an important 
confounding factor to ensure that the selected neoantigens correctly represent the individual’s 
genome132. We have also expanded the supported mutation types for neoantigen predictions 
to include in-frame indels and frameshift mutations. These capabilities expand the potential 
number of targetable neoantigens several-fold in many tumors.  
 
To prioritize neoantigens, pVACseq now offers support for as many as eight different MHC 
Class I epitope prediction algorithms and four MHC Class II prediction algorithms. The tool 
does this by leveraging the Immune Epitope Database (IEDB)135 and their suite of six 
different MHC class I prediction algorithms, as well as three MHC Class II algorithms. 
pVACseq supports local installation of these tools for power-users, or provides 
straightforward access by default via the IEDB RESTful web interface. In addition, pVACseq 
now contains an extensible framework for supporting new neoantigen prediction algorithms 
that has been used to add support for two new non-IEDB algorithms - MHCflurry61 and 
MHCnuggets62. By creating a framework that integrates many tools we allow for (a) a 
broader ensemble approach than IEDB, and (b) a system that other users can leverage to 
develop improved ensemble ranking, or to integrate proprietary or not-yet-public prediction 
software. Importantly, this framework enables non-informatics-savvy users to predict 
neoantigens from sequence variant data sets. 
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Once neoantigens have been predicted, the pVACseq ranking score is used to prioritize them. 
This score takes into account gene expression, sequence read coverage, binding affinity 
predictions, and agretopicity. In addition to applying strict binding affinity cutoffs, the 
pipeline also offers support for MHC allele-specific cutoffs136. Taking a step further than 
most commonly used approaches, we also offer cleavage position predictions via optional 
processing through NetChop137 as well as stability predictions made by NetMHCstab138.  
 
Previous studies have shown that the novel protein sequences produced by gene fusions 
frequently produce neoantigen candidates139. pVACfuse provides support for predicting 
neoantigens from such gene fusions. Fusion variants may be imported in annotated BEDPE 
format from any fusion caller (we used INTEGRATE-Neo139). These variants are then 
assessed for presence of fusion neo-epitopes using predictions against any of the pVACseq-
supported binding prediction algorithms. 
 
Implementing cancer vaccines in a clinical setting requires multidisciplinary teams, many of 
whom may not be informatics savvy. To support this growing community of users, we 
developed pVACviz, which is a browser-based user interface that assists in launching, 
managing, reviewing, and visualizing the results of pVACtools processes. Instead of 
interacting with the tools via terminal/shell commands, the pVACviz client provides a 
modern web-based user experience. Users complete a pVACseq process setup form that 
provides helpful documentation and suggests valid values for inputs. The client also provides 
views showing ongoing processes, their logs, and interim data files to aid in managing and 
troubleshooting. After a process has completed, users may examine the results as a filtered 
data table, or as a scatterplot visualization - allowing them to curate results and save them as 
a CSV file for further analysis. 
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Figure 4.2: pVACviz GUI client: pVACtools provides a browser-based graphic user 
interface, called pVACviz, that provides an intuitive means to launch pipeline processes, 
monitor their execution, and analyze, export, or archive their results. To launch a process, 
users navigate to the Start Page (A), and complete a form containing all of the relevant 
inputs and settings for a pVACseq process. Each form field includes help text, and provides 
typeahead completion where applicable. For instance, the Alleles field provides a typeahead 
dropdown menu that match available alleles. Once a process is launched, a user may monitor 
its progress on the Manage Page (B), which lists all running, stopped, and completed 
processes. The Details Page (C) shows a process’ current log, attributes, and any results files 
as well as providing buttons for stopping, restarting, exporting and archiving the process. 
The results of pipeline processes may be analyzed on the Visualize Page (D), which displays 
a customizable scatterplot of a file's rows. The X and Y axis may be set to any column in the 
result set, and filters may be applied to values in any column. Additionally, points may be 
selected on the scatter plot or data grid (not visible in this figure) for further analysis or 
export as CSV files. 
  
Furthermore, to support informatics groups that want to incorporate or build upon the 
pVACtools features, we developed pVACapi, which provides a HTTP REST interface to the 
pVACtools suite. Currently, it provides the API that pVACviz uses to interact with the 
pVACtools suite. Advanced users could develop their own user interfaces, or use the API to 
control multiple pVACtools installations remotely over an HTTP network. 
 
Once a list of neoantigen candidates has been prioritized and selected, the pVACvector utility 
can be used to aid in the construction of DNA-based cancer vaccines. The input is either the 
output file from pVACseq or a fasta file containing peptide sequences, and pVACvector 
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returns a neoantigen sequence ordering that minimizes the effects of junctional epitopes 
(which may create novel antigens) between the sequences. This is accomplished by using the 
core pVACseq services to predict the binding scores for each junctional peptide and by 
testing junctions with spacer140 amino acid sequences that may help to reduce reactivity. The 
final vaccine ordering is achieved through a simulated annealing procedure that returns a 
near-optimal solution, when one exists. 
 
pVACtools has been used to predict and prioritize neoepitopes for several neoantigen 
studies141–143 and cancer vaccine clinical trials (e.g. NCT02348320 and NCT03122106). We 
also have a large external user community (the original ‘pvacseq’ package has been 
downloaded over 37,000 times from PyPi, and the ‘pvactools’ package has been downloaded 
over 9,000 times) that has been actively evaluating and using these packages for their 
neoantigen analysis, and has also helped in the subsequent refinement of pVACtools through 
feedback. 
4.3 Methods 
To demonstrate the utility and performance of the pVACtools package, we downloaded 
exome sequencing and RNA-Seq data from The Cancer Genome Atlas (TCGA)14 from 100 
cases each of melanoma, hepatocellular carcinoma and lung squamous cell carcinoma, and 
used patient-specific MHC Class I alleles (Figure 4.3) to determine neoantigen candidates 
for each cancer.  
 
4.3.1 TCGA data pre-processing 
Aligned tumor and normal BAMs from BWA87 (version 0.7.12-r1039) as well as somatic 
variant calls from VarScan2144,97 (in VCF format) were downloaded from the Genomic Data 
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Commons (GDC, https://gdc.cancer.gov/ ). Since the GDC does not provide germline variant 
calls for TCGA data, we used GATK’s145 HaplotypeCaller to perform germline variant 
calling using default parameters. These calls were refined using VariantRecalibrator in 
accordance with GATK Best Practices121. Somatic and germline missense variant calls from 
each sample were then combined using GATK’s CombineVariants, and the variants were 
subsequently phased using GATK’s ReadBackedPhasing algorithm. 
 
Phased Somatic VCF files were annotated with RNA depth and expression information using 
VCF annotation tools (vatools.org). We restricted our analysis to only consider ‘PASS’ 
variants in these VCFs as these are higher confidence than the raw set, and the variants were 
annotated using the “--pick” option in VEP. 
 
Existing in silico HLA typing information was obtained from The Cancer Immunome Atlas 
(TCIA) database122. 
 
4.3.2 Neoantigen prediction 
The VEP-annotated VCF files were then run through pVACseq using all eight Class I 
prediction algorithms and for epitope lengths 8-11. The current MHC Class I algorithms 
supported by pVACseq are NetMHCpan58, NetMHC57,58, NetMHCcons(Karosiene et al. 
2012), PickPocket59, SMM63, SMMPMBEC64, MHCflurry61 and MHCnuggets62. The four 
MHC Class II algorithms that are supported are NetMHCIIpan, SMMalign, NNalign, and 
MHCnuggets. For the demonstration analysis, we limited our prediction to only MHC Class I 
alleles due to availability of HLA typing information from TCIA, though predictions of Class 
II can be just as easily generated using pVACtools. 
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4.3.3 Ranking of Neoantigens 
To help prioritize neoantigens, a ranking score is assigned where each of the following four 
criteria are assigned a rank-ordered value (where the worst = 1): 
B = binding affinity 
F = Fold Change between MT and WT alleles 
M = mutant allele expression, calculated as (Gene expression * Mutant allele RNA Variant 
allele fraction) 
D = DNA Variant allele fraction 
 
A final ranking is based on a score obtained from combining these values:  
Priority Score = B+F+(M*2)+(D/2).  This score is not meant to be the final word on peptide 
suitability for vaccines, but was designed to be a useful metric. 
 
4.3.4 Pipeline for creation of pVACtools input files 
pVACtools is designed to support a standard VCF variant file format and thus, should be 
compatible with many existing variant calling pipelines. However, as a reference, we provide 
the following description of our current somatic and expression analysis pipeline (manuscript 
in preparation) which has been implemented using docker, CWL146, and Cromwell147. The 
pipeline consists of workflows for alignment of exome/DNA- and RNA-Seq data, somatic 
and germline variant detection, RNA-Seq expression estimation as well as optional HLA 
typing. 
 
This pipeline starts with raw patient tumor exome or cDNA capture148 and RNA-seq data and 
produces annotated VCFs for neoantigen identification and prioritization with pVACtools. 
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Our pipeline consists of three main components: DNA alignment, variant detection and 
annotation, as well as RNA-seq data processing. More specifically, we use BWA-MEM87 for 
aligning the patient’s tumor and normal exome data. The output BAM then undergoes 
merging (Samtools Merge), query name sort (Picard SortSam), duplicate marking (Picard 
MarkDuplicates), position sorting followed by base quality recalibration (GATK 
BaseRecalibrator). GATK’s HaplotypeCaller145 is used for germline variant calling and the 
output variants are annotated using VEP4 and filtered for coding sequence variants.  
 
For somatic variant calling, our pipeline combines the output of four variant detection 
algorithms- Mutect2149, Strelka98, Varscan144,97 and Pindel150. The combined variants are 
normalized using GATK’s LeftAlignAndTrimVariants where the indels are left-aligned and 
common bases are trimmed. Vt151 is used to split multi-allelic variants. Several filters such as 
gnomAD allele frequency, percentage of mapq0 reads, as well as pass-only variants are 
applied prior to annotation of the VCF using VEP. We use a combination of custom and 
standard plugins for VEP annotation (params: --format VCF --plugin Downstream --plugin 
Wildtype --symbol --term SO --transcript_version --tsl --coding_only --flag_pick --hgvs).  
Variant coverage is assessed using bam-readcount (https://github.com/genome/bam-
readcount) for both the tumor and normal DNA exome data and is also annotated into the 
VCF output using VCF-annotation-tools (vatools.org).  
 
Our pipeline also generates a phased-VCF file by combining both the somatic and germline 
variants and running the sorted combined variants through GATK ReadBackedPhasing.  
 
For RNA-seq data, the pipeline first trims the adapter sequence using flexbar152 and aligns the 
patient’s tumor RNA-seq data using HISAT2153. Two different methods, Stringtie154 and 
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Kallisto155, are employed for evaluating both the transcript and gene expression values. 
Additionally, coverage support for variants in RNA-seq data can also be assessed through 
bam-readcount. This information is added to the VCF using VCF-annotation-tools and serves 
as an input for neoantigen prioritization using pVACtools. 
 
Optionally, our pipeline can also run HLA-typing in silico using OptiType48 when clinical 
HLA typing is not available.  
 
4.3.5 Implementation of software 
pVACtools is written in Python3. The individual tools are implemented as separate command 
line entry points that can be run using the `pvacseq`, `pvacfuse`, `pvacvector`, `pvacapi`, and 
`pvacviz` commands to run the respective tool. pVACapi is required to run pVACviz so both 
the `pvacapi` and `pvacviz` command need to be executed in separate terminals. For 
pVACseq, the PyVCF package is used for parsing the input VCF files. The mhcflurry and 
mhcnuggets packages are used to run the MHCflurry and MHCnuggets prediction algorithms, 
respectively. The pandas package is used for data management while filtering and ranking the 
neoantigen candidates in pVACseq and pVACfuse. The simanneal package is used for the 
simulated annealing procedure when running pVACvector. pVACapi is implemented using 
Flask and Bokeh. The pVACviz client is written in TypeScript using the Angular web 
application framework, the Clarity UI component library, and the ngrx library for managing 
application state. The test suite is implemented using the Python unittest framework and 
GitHub integration tests are run using travis-ci (travis-ci.org). Code changes are integrated 
using GitHub pull requests (https://github.com/griffithlab/pVACtools/pulls). Feature 
additions, user requests, and bug reports are managed using the GitHub issue tracking 
(https://github.com/griffithlab/pVACtools/issues). User documentation is written using the 
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reStructuredText markup language and the Sphinx documentation framework (sphinx-
doc.org). Documentation is hosted on Read The Docs (readthedocs.org).  
 
4.4 Results and Discussion 
4.4.1 Analysis of TCGA data using pVACtools 
To demonstrate the utility and performance of the pVACtools package, we downloaded 
exome sequencing and RNA-Seq data from The Cancer Genome Atlas (TCGA)14 from 100 
cases each of melanoma, hepatocellular carcinoma and lung squamous cell carcinoma, and 
used patient-specific MHC Class I alleles  (Figure 4.3) to determine neoantigen candidates 
for each patient. There were a total of 64,422 VEP-annotated variants reported across 300 
samples, with an average of 214 variants per sample. Of these, 61,486 were single 
nucleotides variants (SNVs), 479 were inframe insertions and deletions and 2,465 were 
frameshift mutations (Figure 4.4). We used this annotated list of variants as input to the 
pVACseq component of pVACtools to predict neoantigenic peptides. pVACseq reported 
14,599,993 unfiltered peptide candidates. The original version of pVACseq111 reported 
10,284,467 peptides, and thus, by extending support for additional variant types as well as 
prediction algorithms (due to support for additional alleles), we produced 42% more raw 
candidate neoantigens.  
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(a) 
 
 
 
(b)  
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(c)   
 
Figure 4.3: Patient counts per HLA allele subtype Distribution of HLA-alleles for the entire 
cohort of 300 TCGA patients analyzed in this study is shown in each of the three plots for (a) 
HLA-A allele subtypes (33 unique alleles); (b) HLA-B allele subtypes (67 unique alleles); (c) 
HLA-C allele subtypes (30 unique alleles). The total number of unique HLA alleles found in 
the patient cohort was 130. 
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Figure 4.4: Violin plots showing the distribution of observed variants per cancer type 
summarized for each variant type supported by pVACseq. (A) missense (total variant count: 
61,486), (B) inframe deletion (total variant count: 389), (C) inframe insertion (total variant 
count: 81), and (D) frameshift (total variant count: 2,465).  
 
By applying our default median binding affinity cutoff of 500 nM across all eight MHC Class 
I prediction algorithms, there were 96,235 predicted strong binding neoantigens, derived from 
34,552 somatic variants (32,788 missense SNVs, 1,603 frameshift variants and 131 in-frame 
indels). This set of strong binders was further reduced by filtering out mutant peptides with 
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median predicted binding affinities (across all prediction algorithms) greater than that of the 
corresponding wildtype peptide (i.e. mutant/wildtype binding affinity fold change > 1), 
resulting in 70,628 neoantigens from 28,588 variants (26,880 SNVs, 1,583 frameshift and 
125 in-frame indels).  
 
This set was subsequently filtered by evaluation of exome sequencing data coverage and our 
recommended defaults, as follows. By applying the default criteria of variant allele fraction 
(VAF) cutoff of > 25% in tumor and < 2% in normal sample, with coverage levels of at least 
10X tumor coverage and at least 5X normal coverage, 10,730 neoantigens from 4,891 
associated variants (4,826 SNVs, 56 frameshift and 9 in-frame indels) were obtained, with an 
average of 36 neoantigens predicted per case. Since RNA-seq data also were available, the 
filtering criteria included RNA-based coverage filters (tumor RNA VAF > 25% and tumor 
RNA coverage > 10X) as well as a gene expression filter (FPKM > 1). To condense the 
results even further, only the top ranked neoantigen was selected per variant across all alleles, 
lengths, and registers (position of amino acid mutation within peptide sequence), resulting in 
4,891 total neoantigens with an average of 16 neoantigens per case. This list was then 
processed with pVACvector to determine the optimum arrangement of the predicted high 
quality neoantigens for a DNA-vector based vaccine design (Figure 4.5). 
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Figure 4.5: An example from pVACvector output showing the the optimum arrangement of 
candidate neoantigens for a DNA-vector based vaccine design. The figure shows 
visualization of a circularized DNA insert carrying the encoded neoantigenic peptide 
sequences to be synthesized and encoded/cloned into a DNA plasmid.  DNA sequences 
encoding each peptide are ordered (with use of spacer sequences where needed) to ensure 
there are no strong-binding junctional epitopes. Each neoantigenic peptide candidate is 
shown in Blue,Green, Red, Orange, Purple, and Brown. Spacer sequences, where added for 
minimizing junctional epitope affinity, are depicted in Black, along with the binding affinity 
value of the strongest binding junctional epitope. Labels depict 
MutantIdentifier:GeneName:TranscriptName:TranscriptNumber:TypeofMutation:AminoAcid
Change.  
 
 
4.4.2 Comparison of epitope prediction software 
Since we offer support for as many as eight different epitope prediction tools, we assessed 
agreement between these algorithms from a random subset of 100,000 peptides (Figure 4.6). 
The highest correlation was observed between the two stabilization matrix method (SMM)-
based algorithms - SMM and SMMPMBEC. The next best correlation was observed between 
NetMHC and MHCflurry.  
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Figure 4.6: Spearman Correlation between prediction values This figure shows a heatmap 
of the Spearman correlation between binding affinity predictions from all eight algorithms 
generated from random subsample set of size 100,000 peptides 
 
 
keWe also evaluated if there were any biases within the algorithms to predict strong (i.e. 
binding affinity < = 500nM) or weak binding epitopes (Figures 4.7 and 4.8).  We found that 
MHCnuggets predicts the highest number of strong-binding candidates alone. Of the total 
number of strong binding candidates predicted, 64.7% of these candidates were predicted by 
a single algorithm, 35.2% were predicted as strong-binders by two to seven algorithms, and 
only 1.8% of the strong-binding candidates were predicted as strong binders by the 
combination of all eight algorithms. Infact, even if one (or more) algorithms predict a peptide 
to be a strong binder, often another algorithm not only doesn't agree but disagrees by a large 
margin, in some cases predicting that same peptide as a very weak binder. This remarkable 
lack of agreement underscores the potential value of considering multiple algorithms.   
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(a)
 
 
(b) 
 
Figure 4.7: Upset plot between number of peptides and prediction algorithms Intersection 
of peptide sequences predicted by different algorithms are shown using upset plots. The y-
axis shows the number of overlapping unique neoantigenic peptides predicted for each 
combination of algorithm depicted on the x-axis. Each filled black circle shows the sets 
contained in an exclusive intersection (i.e. the identity of each algorithm), while the light 
gray circles represent the algorithm(s) that do not participate in this exclusive intersection. 
(a) Upset plot for the top 20 algorithm combinations ranked by the number of peptides 
predicted to be a good binder (mutant IC50 score < 500 nM). The combination of all eight 
algorithms (highlighted orange) ranks the 8th highest; (b) Upset plot for algorithm 
combinations where at least six algorithms agree on predicting a peptide to be a good binder 
(MT IC50 score < 500 nM). The combination of all eight algorithms (highlighted orange) 
ranks the highest. 
 
 
 95 
 
 
 
Figure 4.8: Number of peptides predicted to be good binders (MT IC50 Score < 500 nM) 
versus number of algorithms used. 
 
Next we determined if the number of human HLA alleles supported by these eight algorithms 
differed. As shown (Figure 4.9), MHCnuggets supports the highest number of human HLA 
alleles. 
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(a) 
 
(b) 
  
(c )  
 
Figure 4.9: Human HLA Allele subtype support distribution by eight algorithms (a) 
Number of allele subtypes supported versus number of algorithms; (b) Upset plot for 
algorithm combinations ranked by the number of allele subtypes supported by pVACseq. 
Total number of HLA allele subtypes supported by pVACseq: 9,851. The combination of all 
eight algorithms (highlighted orange) ranks the 3th highest; (C) Upset plot for algorithm 
combinations ranked by the number of allele subtypes supported for the 300 TCGA samples 
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analyzed in this study. Total number of HLA alleles across patient cohort: 130. The 
combination of all eight algorithms (highlighted orange) ranks the 2nd highest. 
 
4.4.3 Comparison of filtering criteria 
Since pVACtools offers a multitude of ways to filter the list of predicted neoantigens, we 
evaluated and compared the effect of each filter in narrowing down high quality neoantigen 
candidates.  
 
We first compared the effect of running pVACtools using the commonly used standard 
binding score cutoff of <= 500nM (parameters: -b 500) versus the newly added allele-specific 
score filter (parameters: -a). These cutoffs were, by default, applied to the “median” binding 
score of all prediction algorithms. 96,235 neoantigens (average 320.78 per patient) were 
predicted using the 500 nm binding score cutoff compared to 94,068 neoantigens (average 
313.56 per patient) using allele-specific filters. About 79% neoantigens were shared between 
the two sets. 
 
We also narrowed further to include only those predictions where the default “median” 
predicted binding affinities (< = 500 nm) are lower than each corresponding median wildtype 
peptide affinity (parameters: -b 500 -c 1) (i.e. a binding affinity mutant/wild type ratio or 
aggretopicity value indicating that the mutant version of the peptide is a stronger binder). 
Using the aggretopicity value filter, 70,628 neoantigens (average 235.43 per patient) were 
predicted versus the previously reported 96,235 neoantigens without this filter. 
 
We also evaluated the effect of the aggretopicity value filter when applied to the set of 
epitopes filtered on “lowest” binding score of < = 500 nm ( parameters: -b 500 -c 1 -m 
lowest). This filter reports peptides where at least one of the algorithms predicts a strong 
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binder, instead of calculating a median score and requiring that to meet the 500 nm threshold 
(Figure 4.10).  Using the lowest binding score filter resulted in an 11-fold increase in the 
number of candidates predicted (827,423 candidates, average 2,758.08 per patient). 
 
(a)  
 
 
 
(b) 
 
Figure 4.10: Overall of distribution of binding affinity scores (nM) for peptides where at 
least one of the algorithms predicts a strong binder. HLA allele subtype-specific thresholds 
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are applied when available, otherwise the default cutoff binding affinity of 500 nM is used. 
Peptides with predicted MT IC50 scores lower than their respective cutoff scores are 
highlighted in orange. The median MT IC50 scores of each algorithm’s prediction are 
marked for reference. (a) Original data on logarithmic scale; (b) A ceiling of 1000 nM is 
applied to the MT IC50 scores. 
 
 
Using the median (default) binding affinity filtering criteria, we next applied coverage and 
expression based filters. First, we filtered using the recommended defaults i.e. greater than 
5X normal DNA coverage, less than 2% normal VAF, greater than 10X tumor RNA and 
DNA coverage and greater than 25% tumor RNA and DNA VAF, along with FPKM > 1 for 
transcript level expression (parameters: --normal-cov 5 --tdna-cov 10 --trna-cov 10 --normal-
vaf 0.02 --tdna-vaf 0.25 --trna-vaf 0.25 --expn-val 1). A total of 10,730 neoantigens were 
shortlisted across all samples with an average of 35 neoantigens per case. We then compared 
this set with a slightly more stringent criteria using tumor DNA and RNA VAF of 40% 
(parameters: --tdna-vaf 0.40 --trna-vaf 0.40). This shortened our list of predicted neoantigens 
to 4,073 candidates averaging to 13 candidates per patient. 
 
Lastly, we applied our top binding score filter to select the best candidate neoantigen per 
variant across all alleles and all lengths (one result per variant) using the previously described 
default filters. This resulted in a final list of 4,891 neoantigens across 300 patients. 
 
4.4.4 Demonstration of neoantigen analysis using pVACfuse 
To demonstrate the potential of neoantigens resulting from gene fusions, we analyzed TCGA 
prostate cancer RNA-seq data from 302 patients. This dataset was used as a demonstration set 
for the neoantigen prediction supported by Integrate-Neo. We wanted to assess the difference 
(if any) in neoantigens candidates reported by INTEGRATE-Neo139 using the one MHC 
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Class I prediction algorithm it supports (NetMHC) versus an ensemble of eight Class I 
prediction algorithms supported in pVACfuse. 
 
Using 1,619 gene fusions across 302 samples as input, pVACfuse reported 2,104 strong 
binding neoantigens (binding affinity <= 500nM) resulting from 739 gene fusions. On 
average, there were about 7 neoantigens per sample resulting from an average of 2 fusions 
per case. This is an eight fold increase in the number of strong binding neoantigens predicted 
by pVACfuse versus the ones reported by INTEGRATE-Neo, which reported 261 
neoantigens across 210 fusions. 
 
4.5 Conclusion 
As reported from our demonstration analysis, a typical tumor has too many possible 
neoantigen candidates to be practical for a vaccine. There is therefore a critical need for a tool 
that takes in the input from a standard sequencing analysis pipeline and reports a filtered and 
prioritized list of neoantigens. pVACtools enables a streamlined, accurate and user-friendly 
analysis of neoantigenic peptides from NGS cancer datasets. This suite offers a complete and 
easily configurable end-to-end analysis, starting from somatic variants and gene fusions 
(pVACseq and pVACfuse respectively), through filtering, prioritization, and visualization of 
candidates (pVACviz), and determining the best arrangement of candidates for a DNA vector 
vaccine (pVACvector). Furthermore, by supporting additional classes of variants as well as 
gene fusions, we offer an increase in the number of predicted epitopes which is even more 
important in the case of low mutational burden tumors. Finally, by extending support for 
multiple binding prediction algorithms, we allow for a consensus approach. The need for this 
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integrated approach is made abundantly clear by the high disagreement between these 
algorithms observed in our demonstration analyses. 
 
The results from pVACtools analyses are already being used in cancer immunology studies, 
including studying the relationship between tumor mutation burden and neoantigen load to 
predict response in checkpoint blockade therapy trials and the  design of cancer vaccines in 
ongoing clinical trials. We anticipate that pVACtools will make such analyses more robust, 
reproducible, and facile as these efforts continue.  
 
4.6 Data availability 
Data from 100 cases each of melanoma, hepatocellular carcinoma and lung squamous cell 
carcinoma were obtained from TCGA and downloaded via the Genomics Data Commons 
(GDC). This data can be accessed under dbGaP study accession phs000178. Data for 
demonstration and analysis of fusion neoantigens was downloaded from the Github repo for 
Integrate (https://github.com/ChrisMaherLab/INTEGRATE-Vis/tree/master/example). 
 
4.7 Software availability 
The pVACtools codebase is hosted publicly on GitHub at 
https://github.com/griffithlab/pVACtools and https://github.com/griffithlab/BGA-interface-
projects (pVACviz). User documentation is available at pvactools.org. This project is 
licensed under the Non-Profit Open Software License version 3.0 (NPOSL-3.0, 
https://opensource.org/licenses/NPOSL-3.0). pVACtools has been packaged and uploaded to 
PyPi under the “pvactools” package name and can be installed on Linux systems by running 
the `pip install pvactools[API]` command. Installation requires a Python 3.5 environment 
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which can be emulated by using Conda. Versioned Docker images are available on 
DockerHub (https://hub.docker.com/r/griffithlab/pvactools/). 
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Chapter 5: Conclusion and future 
directions  
 
Neoantigen prediction accuracy  is a critical factor in the widespread adoption of cancer 
vaccine-based immunotherapy, as vaccine efficacy depends on selection of the best 
neoantigens.  The approaches developed in this work should help to identify, evaluate and 
characterize tumor-specific neoantigens in a much-reduced time, thereby increasing the  
applicability of cancer vaccines for clinical use.  
 
Preliminary studies in human patients have shown that only a subset of candidate antigens 
predicted by existing methods elicit an immune response when administered as a vaccine72. 
In fact, only about 16–43% of the predicted neoantigenic peptides included in a vaccine 
formulation for any reported clinical trial to-date yield a CD8+ T cell response. This lack of 
accuracy in prediction may emerge from several sources of uncertainty in neoantigen 
prediction, including the inability to identify which of the predicted neoantigenic peptides 
with high binding affinity will be processed and presented to the immune system by the 
MHC. This aspect is not readily predicted computationally, although there are several 
algorithms available to perform these predictions 137.  Hence, there is a critical need for an 
approach that learns from the response data obtained from clinical cancer vaccine  trials and 
uses the information to refine  neoantigen predictions for future trials. We have hypothesized 
that a machine learning approach might help in refining these predictions such that a higher 
percentage of the neoantigens are  able to induce T-cell immunity when administered in the 
cancer vaccine.  Hence, we have initiated an effort to curate these data from multiple clinical 
trials and to implement a machine learning-based approach. 
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Pursuit of machine learning will require several components, outlined below: 
Construct target variable(s) 
To assess ‘good’ vaccine candidates, we will first need to define appropriate criteria to 
construct a target variable(s) as an indicator of immunogenicity. Different immunology labs 
may use different metrics for such an analysis, and since not all labs actively use neoantigens 
for vaccination per se, some data mining will be required to determine which assays are used 
routinely. This will help in narrowing down a common endpoint across different projects to 
assess immunogenicity. Some examples of these assays include ELISPOT/ELISA that 
measures IFNγ production, Peptide–MHC tetramers/dextramer assays, or a combination of 
both. 
  
Obtain data from published and ongoing research 
There are several in-house vaccine clinical trials currently underway as collaborations 
between the McDonnell Genome Institute and the Siteman Cancer Center. For example, the 
Komen Promise Vaccine trial which aims to design and treat triple negative breast cancer 
patients during the window of opportunity following neoadjuvant chemotherapy, surgery and 
radiation therapy, is a  phase I clinical trial that compares synthetic polypeptide-    
(https://clinicaltrials.gov/ct2/show/NCT02427581) to DNA-based vaccines 
(https://clinicaltrials.gov/ct2/show/NCT02348320). Initial results were already  published for 
a first-in-human  vaccine trial in melanoma patients 
(https://clinicaltrials.gov/ct2/show/NCT00683670). There were five patients enrolled in this 
phase 1 vaccine clinical trial employing autologous, functionally mature, interleukin (IL)-
12p70-producing dendritic cells (DC) carrying neoantigens identified by our pipeline.   
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We  also are actively curating previously published research to inform our machine learning 
approach37,41,42,66,156,157. One caveat for these published datasets is the absence of 
transcriptome data in some cases, which will need to be imputed while building the predictive 
model.  
 
Engineer features based on dataset properties 
Since genomic and/or transcriptomic data are now used routinely for assessment of 
neoantigens, it is essential to use this information from such massively parallel sequencing 
studies to select appropriate features for building the machine learning classifier. We may use 
basic aggregators on the given data to engineer meaningful features for the model. Some of 
these features include: 
a) Tumor coverage from DNA and/or RNA 
b) Tumor variant allele fraction from DNA and/or RNA 
c) Gene expression: this may be in the form of FPKM values obtained from RNA-(Cap) 
Seq data or quantitative expression from qPCR. 
d) Binding affinity from epitope prediction algorithms 
e) Fold change in the predicted binding of the mutant epitope versus the wildtype  
  
Additional features such as HLA-type, type of amino acids in the peptide, properties of amino 
acids (hydrophobic, hydrophilic, polar), position of the mutation in the peptide sequence 
(anchor residues, TCR-facing residues) etc. could also be investigated. 
  
Select feature subset 
Since there are several different features associated with sequencing datasets, it may be 
possible that not all features are relevant when building a predictor. Popular feature selection 
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methods such as chi squared and analysis of variance (ANOVA) could be used to retrieve a 
subset of features that have a strong correlation with the target variable. This subset would be 
used by the predictive model to carry out the classification. 
  
Perform predictive modeling 
Once a set of features is finalized, a feature matrix is constructed based on the features 
selected for the study as well the target variable. A predictive model would then be developed 
which would use the feature matrix as input to predict the best set of neoantigens to be used 
for analysis and/or vaccination. There are several different machine learning approaches that 
can be evaluated including neural networks, random forest, support vector machine and deep 
learning approaches. Evaluation is generally done by cross validation techniques such as N-
-fold cross validation, leave one out cross validation, etc. Various metrics like area under the 
ROC curve (AUC), accuracy of the model, precision, recall, F1 score, etc. can be used to 
determine the appropriate classifier. 
  
As we learn from ongoing early human trials, the methods developed in this thesis will help 
in identification, selection and characterization of high quality neoantigens from different 
cancer sequencing datasets. Furthermore, these methods could be directly applied to assist in 
development of immunotherapy based clinical trials and basic immunology studies such as 
studying the relationship between tumor mutation burden and neoantigen load to predict 
response in checkpoint blockade therapy trials and the design of personalized cancer 
vaccines. The computational framework developed in this work (pVACtools) will help 
optimize the composition of personalized cancer vaccines with high precision that will hasten 
vaccine design to enable growing clinical demand. Additionally, as mentioned previously, 
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these methods could even be extended by incorporating the feedback from the growing 
number of trials to improve the prediction of neoantigens and their immunogenicity.  
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